Women responded better than men to early Alzheimer’s intervention, study found – WXOW.com

After age and genetics, being a woman is the single most important risk factor for developing Alzheimer's disease, experts say.

"Two out of every three brains affected by Alzheimer's disease are women's brains," said Dr. Richard Isaacson, director of the Alzheimer's Prevention Clinic in the Center for Brain Health at Florida Atlantic University's Schmidt College of Medicine.

Now, a new study has good news when it comes to giving women a chance to reduce their increased risk. Personalized lifestyle interventions -- such as diet, exercise, stress reduction and sleep hygiene -- were able to reduce Alzheimer's risk factors in both sexes, but they worked even better in women.

"Our individually tailored interventions led to greater improvements in women compared to men across risk scales for Alzheimer's and cardiovascular disease," said Isaacson, who coauthored the paper.

Women also showed greater improvements than men in biomarkers such as lower blood sugar and lower LDL, or low-density lipoprotein, which is the "bad" cholesterol.

"This study clearly reinforces the need for additional larger studies to be able to better predict the baseline cognitive trajectory in aging females versus males," said Rudy Tanzi, a professor of neurology at Harvard Medical School. He is director of the genetics and aging research unit at Massachusetts General Hospital in Boston.

"As we aim to find ways to nip this disease in the bud stage, we will need to know if prevention and treatment strategies will work equivalently on both men and women. This new study clearly brings us a big step closer to that goal," said Tanzi, who was not involved in the study.

The new study followed a subset of people participating in a 10-year study designed to test the impact of personalized recommendations on cognitive function and risk factors for dementia. The Comparative Effectiveness Dementia and Alzheimer's Registry trial, which began in 2018, is being conducted at NewYork-Presbyterian/Weill Cornell Medical Center in New York City.

After full blood, physical, cognitive and genetic workups, patients were provided with individualized genetic counseling and education. Medications, vitamins and supplements were tailored to each person's unique results as well. In addition, all participants received personalized lifestyle interventions, such as counseling on exercise, diet, blood pressure control, sleep hygiene and stress reduction.

Everyone in the CEDAR trial has a family history of Alzheimer's, but the majority had no signs of cognitive decline when the study began, Isaacson said. Of the 154 men and women participating in the research, 35 were diagnosed with mild cognitive impairment, or MCI, due to Alzheimer's, but it was not severe enough to "impact their daily lives," he said.

The original study's main findings were published in 2019. People with MCI saw their performance on cognitive tests for memory and thinking skills improve by nearly 5 points when they followed at least 60% of their lifestyle recommendations (on average, at least 12 of the 21 different recommendations) for 18 months.

However, the 2019 study found that people with mild cognitive impairment who followed less than 60% of the suggestions showed no cognitive improvement -- in fact, they continued to decline by 6 points on average.

The cognitively normal patients with a family history of Alzheimer's disease, called the prevention group, were able to get an "equally impressive" cognitive boost of an average of 4.5 points by following at least some of the lifestyle recommendations. It didn't seem to matter if they followed less than 60% of them, Isaacson said.

"The good news from our study is that there were actually cognitive improvements at 18 months in both women and men when compared to the control populations," Isaacson said. "A lot of the drugs that have been studied aim to delay cognitive decline, but it is harder to show improved cognition over time."

Approximately half of the participants in CEDAR carry at least one APOE gene, which may increase the risk of developing Alzheimer's disease. However, the study found no difference in the intervention's cognitive benefits for those with one or two copies of APOE compared with those without the gene, "so that was also reassuring," Isaacson said.

The new study, published Tuesday in the journal of the Prevention of Alzheimer's Disease, took the original 2019 study a step further by analyzing a subset of participants to see whether there was any difference between men and women when it came to how well the lifestyle interventions work.

"Women have very different and unique risk factors than men for dementia," Isaacson said. "Women have a 39% higher risk of dementia if they have fat accumulating around their midsection.

"And the rapid decline in estrogen during the perimenopause transition can actually be one of the most impactful risk factors for developing Alzheimer's pathology in the brain," he said.

In the new analysis, women in the prevention group, who started the trial with no cognitive issues, demonstrated greater improvements than men in two areas: one of two cardiovascular risk scales and in levels of the good cholesterol, HDL, or high-density lipoprotein, which is protective against heart disease.

Women with mild cognitive decline, called the early treatment group, showed greater improvements than men when it came to average blood sugar levels and two cardiovascular risk scales. This female cohort also had more significant improvements in several important cholesterol (or lipid) biomarkers than men in the early treatment group.

For all participants, complying with an additional 10% of the personalized recommendations resulted in an additional 0.9 point improvement for women and 0.41 points of improvement for men on tests of cognition.

How does reducing cardiovascular risk impact future cognition? Because what's good for the heart is good for the brain, experts say.

"Vascular risk factors such as high blood pressure, high cholesterol, high blood sugar or diabetes may not be the cause of Alzheimer's disease, but it can fast-forward Alzheimer's pathology," Isaacson said. "I would prefer to slam on the brakes rather than rev the engine on the path to cognitive decline."

Finding that women were able to reduce their risk even more than men is welcome news, Isaacson said, as it provides a promising area for future study and gives hope that women can tip the battle against Alzheimer's in their favor.

"By treating people in an evidence-based yet safe way, using multiple lifestyle and medical interventions, we've shown that you can really make an impact on brain health," he said.

The-CNN-Wire

& 2022 Cable News Network, Inc., a WarnerMedia Company. All rights reserved.

Visit link:
Women responded better than men to early Alzheimer's intervention, study found - WXOW.com

Synthetic Biology Market Size Worth $37.85 Billion, Globally, by 2028 at 20% CAGR – Exclusive Report by The Insight Partners – PR Newswire

NEW YORK, April 26, 2022 /PRNewswire/ -- The Insight Partners published latest research study on "Synthetic Biology MarketForecast to 2028 - COVID-19 Impact and Global Analysis By Products (Enzymes, Chassis Organisms, Oligonucleotides, and Xeno-Nucleic Acids), Technology (Measurement & Modeling, Cloning & Sequencing, Genome Engineering, Gene Synthesis, Nanotechnology, and Others), and Application (Medical Applications, Industrial Applications, Food and Agriculture, Environmental Applications, and Others)", the global synthetic biology market is expected to grow from $10.54 Billion in 2021 to $37.85 Billion by 2028; it is estimated to grow at a CAGR of 20.0%from 2021 to 2028.

The synthetic biology market growth is driven by the increasing investments in synthetic biology, advancements in biotechnology, and the rising number of start-ups. However, renewed regulations for biotechnology are restricting market growth.

Get Exclusive Access to Sample Pages of Synthetic Biology Market Size - COVID-19 Impact and Global Analysis with Strategic Insights at:https://www.theinsightpartners.com/sample/TIPHE100000960/

Report Coverage

Details

Market Size Value in

US$ 10.54 Billion in 2021

Market Size Value by

US$ 37.85 Billion by 2028

Growth rate

CAGR of 20.0% from 2021 to 2028

Forecast Period

2021-2028

Base Year

2021

No. of Pages

217

No. Tables

111

No. of Charts & Figures

84

Historical data available

Yes

Segments covered

Products, Technology, and Application

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Synthetic Biology Market: Competitive Landscape and Key Developments

In August 2021, New England Biolabs announced the release of its newest loop-mediated is sthermal amplification (LAMP) products: the WarmStart Multi-Purpose LAMP/RT-LAMP 2X Master Mix (with UDG) and the WarmStart Fluorescent LAMP/RT-LAMP Kit (with UDG), which combines the master mix and LAMP fluorescent dye in one convenient kit. The new master mix and kit enable researchers to perform rapid, high-throughput detection of targeted segments of DNA or RNA using various amplification detection methods.

In April 2022, Agilent Technologies Inc. announced the expansion of CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx as an aid in identifying esophageal squamous cell carcinoma patients for treatment with Bristol Myers Squibb's PD-1-targeted immunotherapeutic OPDIVO (nivolumab), in combination with fluoropyrimidine and platinum-based chemotherapy or OPDIVO in combination with YERVOY (ipilimumab). These combined treatments provide new hope for patients diagnosed with these cancers.

In April 2022, Merck KGaA launchedthe first-ever antibody to achieve ACT label designation. ZooMAb antibodies received the lowest Environmental Impact Factor (EIF) scores in the chemicals and reagents category.

Place Your Inquiry Before Buying: https://www.theinsightpartners.com/inquiry/TIPHE100000960/

Global synthetic biology market is segmented by region into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for synthetic biology. Asia Pacific is expected to account for the fastest global synthetic biology market growth.. Asia-pacific region will have lucrative growth opportunities during the forecast period due to government initiatives taken in the region. For instance, in November 2017, China launched the first synthetic biology association to support the market's growth. This association promotes academic research and communication in synthetic biology; it further enhances the comprehensive competitiveness of the Shenzhen synthetic biology industry and domestic and foreign influence. While, North America has huge market potential, followed by Europe in the overall synthetic biology market, which is attributed to government funds, investments made by the major companies, conferences held for the awareness regarding synthetic biology, technological advancements in the field of genomics, and higher acceptance by the consumers. However, the MEA and SCAM will also show a relatively lower opportunity in the next few years.

Synthetic biology is an emerging concept that has numerous applications in the chemicals, agriculture, pharmaceuticals, and energy industries. Various start-ups offer gene synthesis products/services for biological processes. For example, Benchling provides CAD tools, GenScript offers gene synthesis, Ginkgo Bioworks assists in organism engineering, Transcripts (a bioinformatics company) offers solutions facilitating cloud labs/automation, and Glowee offers consumer products. Further, 56 synthetic biology businesses raised more than US$ 3 billion in equity financing in the first half of 2020, compared to 65 companies raising US$ 1.9 billion during the same period in 2020. The new generation of biopharma businesses uses synthetic biology to improve cell treatment and gene therapy and support early cancer detection. Some synthetic biology firms with the most funding in the first half of 2020 are listed below.

Table 1. Synthetic Biology Firms with Most Funding in First Half of 2020

Company

Description

Funding

Sana Biotechnology

Biotechnology, Health Care, Life Sciences, and Product Research

US$ 700 million

Impossible Foods

Food & Beverage and Nutrition

US$ 500 million

Moderna Therapeutics

Biotechnology, Genetics, Health Care, Medical, and Pharmaceutical

US$ 483 million

Apeel Sciences

Agriculture, AgTech, Biotechnology, and Food Processing

US$ 250 million

Memphis Meats

Food & Beverage and Nutrition

US$ 161 million

Connect With Our Research Analyst On: https://www.theinsightpartners.com/speak-to-analyst/TIPHE100000960

Synthetic Biology Market: Segmental Overview

The synthetic biology market, based on product, is segmented into oligonucleotides, chassis organisms, enzymes, and xeno-nucleic acid. The oligonucleotides segment is likely to hold the largest share of the market in 2021. Moreover, the same segment is anticipated to register the highest CAGR in the market from 2021-2028. This is mainly because of the rising application of oligonucleotides in genetic testing/ assays and forensic sciences. Based on technology, the market is segmented into, gene synthesis, genome engineering, measurement & modeling, cloning & sequencing, nanotechnology, and others. In 2021, the gene synthesis segment is likely to hold the largest share of the market. However, the genome engineering segment is expected to grow in demand at the fastest CAGR of 20.8% from 2021 to 2028. Based on application, the market is segmented into medical applications, industrial applications, environmental applications, food and agriculture, and others. The medical applications segment is further segmented into drug discovery & therapeutics and pharmaceuticals. In 2021, the medical applications segment is likely to hold the largest share of the market. Moreover, the similar segment is expected to witness growth in its demand at the fastest CAGR of 20.8% from 2021 to 2028.

North America synthetic biology market includes consolidated markets for countries such as the US, Canada, and Mexico. In recent years, all the three countries in the region are witnessing a sequential change in the synthetic biology market. By geography, North America held the largest global synthetic biology market share. This largest share can be attributed to government funds, investments made by the major companies, conferences held for awareness regarding synthetic biology, technological advancements in genomics, and higher consumer acceptance. Synthetic biology is a major tool for biological advances, which helps in providing potential for the development of biological weapons. Security issues can be avoided by regulating the biotechnology industry through policy legislation.

Buy Premium Copy of Synthetic Biology Market Size, Share, Revenue, Strategic Insights and Forecasts 2021-2028 Research Report at: https://www.theinsightpartners.com/buy/TIPHE100000960/

The various government initiatives and funding offered are becoming great support for the synthetic biology market to grow in the US. For instance, according to a report by National Center for Biotechnology Information (NCBI), the US government offers approximately US$ 220 million every year toward synthetic biology research and development.

Browse Adjoining Reports:

Synthetic Biology Technology MarketForecast to 2028 - COVID-19 Impact and Global Analysis ByType (Gene Synthesis, Genome Engineering, Sequencing, Bioinformatics, Cloning, Site-Directed Mutagenesis, Microfluidics, Nanotechnology); Application (Medical, Industrial, Food and Agriculture, Others) and Geography.

Oligonucleotide Synthesis Market Forecast to 2027 Global Analysis by Product (Synthesized Oligonucleotides, Reagents, and Equipment), Application (Research, Diagnostics, and Therapeutics), and End User (Academic Research Institutes, Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, and Other End Users).

Gene Synthesis Market to 2025 - Global Analysis and Forecasts By Products & Services (Services, Consumable, Software), Application (Research & Development Activities, Diagnostics, Therapeutics, Others) End Users (Academic & Research Institutes, Biotech & Pharmaceutical Companies, Diagnostic Laboratories, Others) and Geography.

Genomics MarketForecast to 2027 - COVID-19 Impact and Global Analysis by Technology (Sequencing, Microarray, PCR, Nucleic Acid Extraction and Purification, and Others), Product & Service (Instruments/Systems, Consumables, and Services), Application (Diagnostics, Drug Discovery and Development, Precision/Personalized Medicine, Agriculture & Animal Research, and Others) and End User (Research Centers, Hospitals and Clinics, Pharmaceutical & Biotechnology Companies, and Others).

Molecular Biology Enzymes, Kits, and Reagents MarketForecast to 2028 - COVID-19 Impact and Global Analysis By Product (Enzymes and Kits & Reagents), Application (Epigenetics, Sequencing, Synthetic Biology, Polymerase Chain Reaction, and Other), End User (Biotechnological & Pharmaceutical Companies, Hospitals & Diagnostic Centres, and Academic & Research Institutes), and Geography.

Genome Editing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology (CRISPR, TALEN, Antisense, and Others), Application (Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug Discovery, and Others), and End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Clinical Research Organizations).

Biohacking Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Sensors, Smart Drugs, Strains, Wearables, Others); Application (Synthetic biology, Genetic engineering, Forensic science, Diagnosis and treatment, Drug testing, Others); End User (Pharmaceutical and biotechnological companies, Forensic laboratories, Others) and Geography.

Enzymatic DNA Synthesis Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Custom DNA Synthesis, DNA Library Synthesis); Application (Synthetic Biology, Genetic Engineering, Therapeutic Antibodies, Vaccine Design, Others); End User (Academic and Research Institutes, Biotech and Pharmaceutical Companies, Diagnostic Laboratories, Other) and Geography.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Sameer JoshiE-mail: [emailprotected]Phone: +1-646-491-9876Press Release: https://www.theinsightpartners.com/pr/synthetic-biology-market

SOURCE The Insight Partners

Read more here:
Synthetic Biology Market Size Worth $37.85 Billion, Globally, by 2028 at 20% CAGR - Exclusive Report by The Insight Partners - PR Newswire

Inside the Pig Heart Transplant and Ethical Dilemma That Followed – Sentient Media

On March 8, 2022, David Bennett died, two months after a team at the University of Maryland Baltimore transplanted a pig heart into his body. Such xenotransplantation has long occupied the public imagination, with one of the earliest examples being the myth of Icarus where the father-son duo grafted bird wings onto their bodies. Bennetts operation has helped reify the groundbreaking potential of xenotransplantation: how an unlimited supply of animal organs could render the transplant list, where 17 people die every day waiting for a donor, obsolete. This promise is enticingly attractive, but what is being lost in all the hype and triumphalism it has elicited?

For one, theres much we still dont know about xenotransplantation, according to Dr. Richard Pierson, Director of the Center for Transplantation Sciences at Massachusetts General Hospital. The Virginia-based company Revivicor used the CRISPR-Cas9 system to add in six genes and knock out four from the pig used for Bennetts operation, but we dont know precisely what the right pig is that we ought to be using, Pierson said. Perhaps the right one is the 3-gene pig from the German team, or maybe its a hypothetical pig with manifold other genetic modifications. To manage the threat of transplant rejection, doctors say theyll need to do more genetic tinkering with the pig heart, as well as more tinkering with the immunosuppressive regimen undergone by the patient. What is the safest way to immunosuppress someone whos had a xenotransplant? Pierson said. We dont know. The transplant protocol for Bennett was probably good enough, but nobody knows if it was the best.

Theres also the open question of whether xenotransplantation might enable zoonoses, or the jumping of pathogens across the species divide. Revivicor took extensive steps to ensure a clean pig, from performing a cesarean section of the pregnant sow, to not allowing the piglets to suckle their mother, to maintaining a hermetically sealed pig-in-the-bubble environment. But, despite all this external control, there are porcine endogenous retroviruses that remain and might be a problem according to Pierson. Hes quick to clarify that the existing evidence suggests these endogenous retroviruses dont get into actual humans in any productive way. We dont think thats going to be a major barrier, but it remains unknown, Pierson said.

These are all known unknowns, but Piersons main unanswered question is the unknown. Is there some pathogen out there? How will we know its there? How will we respond if we see it? he asked rhetorically. Revivicor can do all the testing it wants to ensure a clean pig, but how can they test for something they dont even know to look for? Theres going to be a tremendous amount to learn before all these questions are answered, Pierson said. But this does not mean we should abandon ship. For Pierson, it just means we should take cautious steps forward.

Bennetts operation inevitably draws historical comparisons to that of Baby Fae, a case that many agree was catastrophically premature. Baby Fae was a 12-day-old infant who, diagnosed with hypoplastic left heart syndrome, received a walnut-sized baboon heart at Loma Linda University in 1984. Baby Fae died 21 days after the operation because of transplant rejection, and her story became an ethical lightning rod, eliciting accusations of inadequate informed consent, medical hubris, and human experimentation. Of course, animal rights activists also raised the issue of exploiting nonhuman primates. Dr. Leonard Bailey, the surgeon behind the operation, dismissed these concerns, saying, When it gets down to a human living or dying, there shouldnt be any question.

But maybe there should be. These animals are very close to us. Theyre experiencing pain, friendship, and love. How can you experiment on them and use them for parts? asked Dr. Sharon Kaufman, Chair of the Department of Anthropology, History, and Social Medicine at the University of California San Francisco. Its the central question that has haunted animal experimentation since its inception: How are animals similar enough to be our model organisms yet different enough to be exploited for our ends?

According to Kaufman, xenotransplantation is an expression of our manifest destiny to expand the limits of human life beyond what was previously imaginable. Its the tyranny of potential whereby progress can march triumphantly, unimpeded by calls for reflection and pause. There used to be no potential. Now its all potential, Kaufman said. Thats whats changed in medicine over the past 50 to 60 years. If something is available, no matter how experimental, no matter how far-fetched, no matter if it even works, it becomes ethically appropriate, necessary, and standard.

Norman Shumway, the father of heart transplantation, once said xenotransplantation is the future of transplantation, and always will be. But, with science fiction now becoming our reality, we have to confront renewed questions about our relationship with animals and how we should navigate the interface between our species and others. As Pierson makes it clear, xenotransplantation isnt quite ready for showtime, but its speeding down to realize its potential, whether we like it or not. By cutting past the hype and triumphalism though, animal rights activists, anthropologists, and the public at large can help shape the path xenotransplantation takes, paving a way that is more informed, cautious, and as humane as possible.

Read More

Were Not Terrible People: Animal Farmers Find Their Voice

Britains Most Iconic Animal Is Under Attack

How Cultivated Meat Went from Lab Experiment to Legitimate Solution

Follow this link:
Inside the Pig Heart Transplant and Ethical Dilemma That Followed - Sentient Media

Autolus Therapeutics (AUTL) Granted Regenerative Medicine Advanced Therapy Designation to obe-cel – StreetInsider.com

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Autolus Therapeutics plc (Nasdaq: AUTL) today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead gene therapy obecabatagene autoleucel (obe-cel), a CD19-directed autologous chimeric antigen receptor (CAR) T therapy that is being investigated in the ongoing FELIX Phase 2 study of adult relapsed / refractory B-Acute Lymphocytic Leukemia (ALL).

The FDA grants RMAT designation to drug candidates in recognition of the therapys potential to address significant unmet medical needs in patients with serious or life-threatening conditions. RMAT designation provides important benefits in the drug development process, designed to facilitate and expedite development and regulatory review.

RMAT designation is an important regulatory milestone for obe-cel and highlights its potential to address the unmet medical need for adult patients with relapsed and refractory B-ALL, said Dr. Christian Itin, Chief Executive Officer of Autolus. RMAT designation from FDA, PRIME designation from EMA and ILAP designation from MHRA facilitate regulatory interactions with key health authorities and supports our drive to bring this innovative therapy to patients as quickly as possible.

obe-cel has previously been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) and Innovative Licensing and Access Pathway (ILAP) by the Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom.

Originally posted here:
Autolus Therapeutics (AUTL) Granted Regenerative Medicine Advanced Therapy Designation to obe-cel - StreetInsider.com

ERC Advanced Grant for cardiac research at the MDC – EurekAlert

image:Artificial heart tissue can contract against a resistance and then relax. view more

Credit: Michael Gotthardt, MDC

The contractile and elastic properties of the heart are finely tuned. This is a prerequisite for the cardiac cycle and efficient adaptation. At the MDC, Michael Gotthardt investigates the underlying molecular and biomechanical mechanisms. He is awarded with an ERC Advanced Grant for this work.

MERAS is the acronym on the recently approved project proposal. It stands for: Mechanoregulation of alternative splicing. We would like to understand how the heart responds to environmental factors and adjusts its elastic properties such that it can function at an optimal level, says Michael Gotthardt. He heads the research group Neuromuscular and Cardiovascular Cell Biology at the Max Delbrck Center for Molecular Medicine in the Helmholtz Association (MDC). For his project, he now receives an Advanced Grant of 2.5 million from the European Research Council (ERC).

This ERC Advanced Grant is awarded to scientists with more than ten years of research experience who have already played a prominent role in their field. Out of the 1,735 researchers from across Europe who applied for the grants this year, 253 were successful.

The mechanical work of the heart depends on the sarcomere, the smallest contractile unit. Here, actin and myosin filaments facilitate contraction, while the giant protein titin determines the elastic properties of heart muscle cells. Different titin variants (isoforms) are expressed perfectly adapted to the mechanical needs. The researchers wish to investigate the underlying process alternative splicing in detail.

Refined regulatory feedback

Our recent analysis of sarcomeric protein composition not only identified the expected structural proteins, but also proteins that link to cell signalling, metabolism, the regulation of gene expression and alternative splicing. These are proteins you would normally expect in the nucleus but not in the sarcomere, emphasizes Michael Gotthardt. It appears that the sarcomere directly communicates with the nucleus on necessary adaptations. The unexpected feedback from sarcomere to spliceosome could explain how sarcomeres adjust to mechanical stress. This is a new hypothesis that the researchers will explore in depth.

A detailed understanding of the regulatory process could also have therapeutic relevance e.g. for people with heart failure. For most of these patients, the ventricular walls have become so rigid that the chambers are no longer able to fill sufficiently. A drug that interferes with the communication from sarcomere to spliceosome could make a stiff cardiac ventricle more compliant, resulting in more efficient filling.

A second ERC grant

This year, the ERC selection process was not solely based on the submitted proposals, but for the first time included short presentations online of course due to Covid 19. Four slides in eight minutes for a 2.5 million euro project, recounts Michael Gotthardt, who is also Professor of Experimental and translational cardiology at Charit Universittsmedizin Berlin. For the scientist, this is already the second substantial contribution from the EU following his ERC Starting Grant in 2011. It extends over a period of five years. This enables us to build up lasting collaborations and projects with extended time lines. And deep sequencing as a prerequisite to evaluate alternative splicing at scale would otherwise be prohibitively expensive.

Gotthardts team works with genetic mouse models, synthetic heart tissue derived from patient cells and isolated heart muscle cells (cardiomyocytes). Single cell mechanics is precision work. For this, the cardiomyocytes first need to be isolated, secured under a special microscope and electrically stimulated. Then you can derive the active and passive forces, says Michael Gotthardt. This would provide the properties of just one single cell. However, for a convincing study, a large number of these experiments need to be conducted.

The goal: new technologies for single-cell mechanics and multi-omics

Extensive manual work is also required to understand which titin isoforms are expressed in response to stress or disease. Compared to a large piece of tissue, a single cell contains relatively few RNA molecules which means that analysis of gene expression frequently reaches the detection limit.The analysis of alternative splicing is even more difficult for giant titin isoforms with up to 100,000 bases. Here, available short reads need to be assembled like a jigsaw puzzle that misses important pieces, says Michael Gotthardt. With the ERC funding, among other things, he plans to develop technologies for single cell mechanics, -transcriptomics, -proteomics that will facilitate multi-omics approaches and enable higher rates of throughput.

The Max Delbrck Center for Molecular Medicine (MDC)

The Max Delbrck Center for Molecular Medicine in the Helmholtz Association (MDC) is one of the worlds leading biomedical research institutions. Max Delbrck, a Berlin native, was a Nobel laureate and one of the founders of molecular biology. At the MDCs locations in Berlin-Buch and Mitte, researchers from some 60 countries analyze the human system investigating the biological foundations of life from its most elementary building blocks to systems-wide mechanisms. By understanding what regulates or disrupts the dynamic equilibrium in a cell, an organ, or the entire body, we can prevent diseases, diagnose them earlier, and stop their progression with tailored therapies. Patients should benefit as soon as possible from basic research discoveries. The MDC therefore supports spin-off creation and participates in collaborative networks. It works in close partnership with Charit Universittsmedizin Berlin in the jointly run Experimental and Clinical Research Center (ECRC ), the Berlin Institute of Health (BIH) at Charit, and the German Center for Cardiovascular Research (DZHK). Founded in 1992, the MDC today employs 1,600 people and is funded 90 percent by the German federal government and 10 percent by the State of Berlin.www.mdc-berlin.de

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See the rest here:
ERC Advanced Grant for cardiac research at the MDC - EurekAlert

He had an M.D. and a Ph.D. but didn’t match into a residency. It was the push he needed to jump into health tech – STAT

Travis Hughes had been assured by both mentors and peers that he was a front-runner for a super-competitive dermatology residency: He had a double degree from Harvard University, experience as a clinical scientist at a health tech startup, and a CV with nearly 40 publications and four patents. Still, during Match Week in March, he failed to land a residency slot, along with 7.1% of fourth-year medical students in the U.S.

While many in his position were upset, Hughes said he was relieved. His part-time job at a startup had nudged him toward industry. The push from the Match was all he needed to set out on this new path. Now, he could forgo the long hours and low pay of residency for a comfortable lifestyle in industry.

From the start of medical school, Hughes had dreamed of eventually founding a biotech company that could sell low-cost drugs, devices, and diagnostics, while he practiced medicine to inform his industry work. His vision to transition from academic medicine to industry put him in good company. Of 2,969 new recipients of a Ph.D. in the life sciences surveyed in 2020, 43% reported that they had committed to a job in industry or business a 10-point jump from 2015, according to the Survey of Earned Doctorates, administered by the National Center for Science and Engineering Statistics. Only 37% reported they would continue down the academic path a 9-point decrease from 2015.

advertisement

With both an M.D. and a Ph.D., Hughes is one of those graduates set on a departure from academia. His story provides a window into why so many others have made the same choice.

After dinner one evening in 2020, Hughes wife, Melany Park, newly in her third trimester of pregnancy, said she had an upset stomach. When she went to the bathroom, she realized it was more serious: She was losing blood fast, after her placenta, which had nourished her fetus, had broken off from the inside of her uterus. Park was rushed to the hospital for an emergency C-section, and at 29 weeks, their daughter Isla was born prematurely. She spent the next two months in the intensive care unit.

advertisement

Park and their daughter have recovered, but the medical crisis changed how Hughes viewed residency, and how to balance his career ambitions with his family. Isla needs a roster of specialists, including a neonatologist and an occupational therapist, who help ensure that she meets her childhood developmental milestones. So Hughes narrowed his selection for residency to five programs near their home in Massachusetts and in other cities with appropriate early childhood services and where his wife could find work as an architect.

He knew he was taking a risk, especially as a candidate for dermatology, a specialty that nearly 20% of U.S. applicants fail to match into. But now in his mid-30s, with a wife and child to support at home, if he couldnt do residency on his own terms, Hughes was fine with not going at all. The Match system forces desperation in people, he said. I didnt want that lack of control.

Hughes applied to medical school because he wanted to make a direct positive impact on a persons life. As a boy, he watched his father care for his grandmother, who struggled to breathe as emphysema destroyed the airways in her lungs. After he earned his masters degree, in need of a job and a place to live while he applied to medical school, Hughes became an in-home caregiver himself after he responded to an advertisement on Craigslist, posted by a man with multiple sclerosis. In the second year of his doctorate program, Hughes reprised that role, this time with Park, his then-fiance: At Harvard, they lived with and cared for Jack L. Strominger, a renowned immunologist.

We're hosting events nationwide (and virtually) to tackle the biggest questions in health and medicine. Browse our upcoming events to see what's on the horizon.

That same desire to help others was what drove him to embark on the long and grueling road of medical training. During his first year at Harvard, he worked in a lab that developed Seq-Well, a cost-effective, portable way to analyze gene expression in cells. With all the tools he needed in a black Pelican case, he traveled to South Africa, the first of many countries on six continents that he would visit to share the technique, which helped galvanize scientific research, especially in places with limited resources.

Inspired by that work, he decided to pursue a doctorate degree in immunology on top of a medical degree. Hughes was encouraged by Strominger to pursue big science questions that fascinated him like how the immune system fights tuberculosis, or how cells mutate in metastatic cancer.

Hughes said that while he enjoyed his time in the lab, fatigue set in: He spent long hours refining lab techniques, writing papers, and traveling to share research globally. As he wearied in the latter phases of his Ph.D., he heard of a company called nference, a local health tech startup. He applied and got a job as a clinical scientist there to help support his family during medical training. It was a breath of fresh air, he said.

He found he was drawn to industry, more so than to working in academic medicine. He felt a weight off his shoulders when he thought of a life free of hustling to publish research, win grants, and earn academic promotions. In exchange for 80-hour work weeks as a resident physician, he envisioned being home to see his toddler grow up. He considered, as well, that an industry salary would provide a far more livable wage: For an entry-level position, he was offered more than four times the median salary of a resident.

Money feels more straightforward, compared to the currencies of authorship, attribution, and credit in academia, said Hughes. In addition, the startup felt team-oriented in a refreshing way. He was especially pleased that the mission of his work, which uses AI to analyze health records, aligned with what motivated him to apply to medical school in the first place: to improve care for patients.

When the news came on the third Monday of March that Hughes had not matched into residency, he felt no pressure to scramble for leftover spots. He was offered an empty position for a clinical scientist at a dermatology residency on the West Coast, but he turned it down. He said he would have felt selfish if he had picked up his family and moved them to the opposite side of the country. He thought of the two paths before him. In industry, he felt he still could make a positive impact that would aid the work of frontline health care workers, and he still could pursue scientific questions that were challenging and exciting. So he chose to transition to a full-time role as a clinical scientist at nference.

For Hughes, no door remains closed, but he says he would be hard-pressed to apply to residency again. He recently caught up with Strominger, both a mentor and the recipient of his care. Uncertain of how Strominger would react, he told him that he planned to pivot to industry. Now retired from working in the lab, Strominger gave his blessing to Hughes for the next step in his journey.

Even in his 90s, you could still find Strominger in the lab, asking new research questions, looking at slides under a microscope, and having his eyes light up when he learned something new. He had a storied career: He won the Lasker Award in 1995 and trained directly or by lineage most of the immunologists at Harvard.

But for Hughes, that sort of career just never felt like exactly what I wanted, he said. Now, I have an opportunity to rethink my life and help others re-envision their path as well.

See the original post here:
He had an M.D. and a Ph.D. but didn't match into a residency. It was the push he needed to jump into health tech - STAT

SKUAST-K to hold international conference on regenerative medicine – Rising Kashmir

Srinagar, Apr 26: Sher-e-Kashmir University of Agricultural Sciences and Technology of Kashmir in association with the Indian Institute of Technology, Kanpur and the University of Kashmir is organising a two-day international conference on Recent Advances in Biomedical Sciences and Regenerative Medicine (RABSRM 2022) on May 6&7.

The conference is being organised as part of the Scheme for Promotion of Academic and Research Collaboration (SPARC) programme, Ministry of Education (MoE), Government of India, that aims at improving the research ecosystem of Indias higher educational institutions. Department of Science and Technology, GoI& World Bank-ICAR funded National Agricultural Higher Education Project for the institutional development of SKUAST-K are also supporting the event.

Department of Biological Sciences and Bioengineering, IIT Kanpur; Division of Animal Biotechnology, SKUAST-K; and Centre for Interdisciplinary Research and Innovations, KU are jointly organising the event to be held at SKUAST-K, Shalimar campus and KU campus, Hazratbal on May 6&7 respectively.

To review the preparations for the international conference, a meeting was held at SKUAST-K under the chairmanship of Director Research, Sarfaraz Ahmad Wani and Dean Faculty of Veterinary Sciences, MT Banday in which scientists, faculty members and organisers of the conference participated.

The mega-conference is being held under the patronage of VC KU Prof Talat Ahmad and VC SKUAST-K Prof Nazir AhamdGanai. Prof Ganai, in his message, highlighted the importance of the conference in the present scientific era and hoped that it will provide an opportunity to discuss and deliberate on the issues shared across related fields concerning the improvement in life and working of mankind.

The RABSRM 2022 conference aims to bring together experts, researchers, young scientists and academicians from around the world to disseminate knowledge from interdisciplinary backgrounds. The knowledge provided by the eminent speakers and researchers will help to foster the research culture in the area of biomedical sciences and regenerative medicine at the universities of Jammu and Kashmir and around the country. The conference will provide an opportunity to discuss recent developments in biomedical research in health and diseases and foster future directions in drug discovery and therapeutic interventions. The themes of the conference include Bioengineering, Regenerative Medicine, Cancer Biology, Drug Design and Delivery, Vaccine Biology, Tissue Engineering, Biomaterials, Molecular Therapeutics, Animal Biotechnology, Stem Cell Gene Therapy & Biomarkers.

The conference solicits contributions of abstracts for oral/poster presentations that address themes and topics of the conference. Participants are required to submit their research abstracts online. Students/Postdocs/Faculties can submit abstracts describing original and unpublished results in all the areas of Biomedical Science and Medicine and are invited for the presentation at the conference after the acceptance. The template of the abstract can be found on the website: http://www.rabsrm.org. Among the leading National and International scientists participating in the two days event include the names of Jukka Seppl from Aalto University, Finland, Andreas Nssler from Univesity of Tuebingen, Germany, JouniPartenan Aalto University, Finland and Hanna Isaksson from Lund University, Sweden as Key International Invited Speakers for the event.

The event will be one of its rear kind in this part of the world where the professionals across diverse disciplines will be deliberating on the theme interrelated across all the steams of concern. The event is expected to host renowned professionals from various national and international organisations for the two days here at Srinagar.

Go here to see the original:
SKUAST-K to hold international conference on regenerative medicine - Rising Kashmir

Class of 2022 President’s Engagement, Innovation, and Sustainability Prize Winners – Almanac

Class of 2022 Presidents Engagement, Innovation, and Sustainability Prize Winners

On April 20, University of Pennsylvania Interim President Wendell Pritchett announced the recipients of the 2022 Presidents Engagement, Innovation, and Sustainability Prizes. Awarded annually, the prizes empower Penn students to design and undertake post-graduation projects that make a positive, lasting difference in the world. Each Prize-winning project will receive $100,000, as well as a $50,000 living stipend per team member.

Five seniors were named recipients of the 2022 Presidents Engagement prize. They are Rowana Miller and Manoj Simha for Cosmic Writers and Seungkwon Son, Max Strickberger, and Sam Strickberger for College Green Ventures. Two seniors have received the Presidents Innovation Prize: William Kohler Danon and Lukas Achilles Yancopoulos for Grapevine. Three seniors and two December 2021 graduates received the inaugural Presidents Sustainability Prize. They are Saif Khawaja for Shinkei Systems; Sarah Beth Gleeson, Shoshana Weintraub, and Julia Yan for EcoSPIN; and Eli Moraru for The Community Grocer.

This years prize recipients have selflessly dedicated themselves to improving environmental, health, and educational outcomes for others, said Provost Pritchett. From empowering young people through free creative writing education to building robotics that minimize fish waste to reducing microfiber pollution in the ocean, these outstanding and inspiring projects exemplify the vision and passion of our Penn students, who are deeply committed to making a positive difference in the world.

The 2022 prize recipientsselected from an applicant pool of 71 peoplewill spend the next year implementing the following projects:

Rowana Miller and Manoj Simha for Cosmic Writers: Ms. Miller, a sociology major in the College of Arts and Sciences from New York City, and Mr. Simha, an economics major in the Wharton School from Seattle, will provide equitable opportunities for free creative writing education to K-12 students across the United States, available regardless of socioeconomic background. Their nonprofit, Cosmic Writers, is a transformative tool for developing literacy, communication skills, and a passion for words. They are mentored by Al Filreis, the Kelly Family Professor of English in the School of Arts and Sciences.

Seungkwon Son, Max Strickberger, and Sam Strickberger for College Green Ventures: Mr. Son, a double major in business analytics in the Wharton School and psychology in the College of Arts and Sciences from Allentown, Pennsylvania, along with Max Strickberger, an English major in the College, and Sam Strickberger, an intellectual history major in the College, both from Chevy Chase, Maryland, will build out College Green Ventures, an organization that aims to be a centralized hub for supporting student social entrepreneurs and creating more of them. They are mentored by Tyler Wry, an associate professor of management in the Wharton School.

William Kohler Danon and Lukas Achilles Yancopoulos for Grapevine: Mr. Danon, a history major in the College from Miami, and Mr. Yancopoulos, an environmental studies major in the College of Arts and Sciences and a bioengineering major in the School of Engineering and Applied Science from Yorktown Heights, New York, will work to increase resilience across the healthcare supply chain, with a particular focus on small-to-medium businesses. Grapevine builds upon Mr. Danon and Mr. Yancopouloss inspiring work with Pandemic Relief Supply, a venture that delivered $20 million worth of healthcare supplies to frontline workers at the height of the COVID-19 pandemic. They are mentored by David F. Meaney, the Solomon R. Pollack Professor of Bioengineering and senior associate dean of Penn Engineering.

Saif Khawaja for Shinkei Systems: Mr. Khawaja, a December 2021 graduate of the Wharton School from Dubai, will continue to grow his startup, Shinkei Systems, which builds robotics that minimize fish waste and multiply shelf-life. Shinkeis robotics automate humane Japanese slaughter techniquessimilar to kosher or halal practices for cattleto ensure that every fish makes it to a plate at top quality. Mr. Khawaja is mentored by Jacqueline Kirtley, an assistant professor of management in the Wharton School.

Sarah Beth Gleeson, Shoshana Weintraub, and Julia Yan for EcoSPIN: Ms. Gleeson, from Lexington, Kentucky; Ms Weintraub, from Bala Cynwyd, Pennsylvania; and Ms. Yan, from Cary, North Carolina; are materials science and engineering majors in the School of Engineering and Applied Science. They are pioneering EcoSPIN, an innovative device that captures microfibers at their laundry point source, protecting oceans and waterways. They are mentored by Karen I. Winey, the Harold Pender Professor of Materials Science and Engineering in the department of chemical and biomolecular engineering in Penn Engineering.

Eli Moraru for The Community Grocer: Mr. Moraru, a December 2021 graduate of the College of Arts and Sciences from Washington, D.C., will continue to work on The Community Grocer, a Philadelphia-based nonprofit organization reimagining nutritional assistance to promote health equity and fight food insecurity. He is mentored by Akira Drake Rodriguez, an assistant professor in the Stuart Weitzman School of Designs department of city and regional planning.

This years finalists also included the following seniors: Bema Boateng for Project Reignite the Light, a program designed to improve mental health literacy in Ghana; Hector Cure and Saskia Wright for Accin para la Reincorporacin Profesional, a program to help demobilized women in Colombia; and Joshua Kim, John Ta, and Myahn Walker for CommuniHealth, a community health care partnership in Philadelphia.

These inspiring projects exemplify the wide range of interests that energize our great Penn students and faculty, said Interim Provost Beth A. Winkelstein. They aim to make a tangible difference in peoples lives, bringing our shared commitments to social justice, intellectual creativity, and entrepreneurial drive to some of the worlds most urgent challenges. We are indebted to the faculty advisors and the Center for Undergraduate Research and Fellowships, who worked closely with our students to develop their exciting and innovative initiatives.

The prizes are generously supported by Emerita Trustee Judith Bollinger and William G. Bollinger, in honor of Ed Resovsky; Emerita Trustee Lee Spelman Doty and George E. Doty, Jr.; Emeritus Trustee James S. Riepe and Gail Petty Riepe; Trustee David Ertel and Beth Seidenberg Ertel; Trustee Ramanan Raghavendran; Wallis Annenberg and the Annenberg Foundation; and an anonymous donor.

Read more:
Class of 2022 President's Engagement, Innovation, and Sustainability Prize Winners - Almanac

Global changemakers: University of Chemistry and Technology, Prague – Study International News

The University of Chemistry and Technology, Prague (UCT Prague) was founded in 1952 as far more than just an institute of higher education, but as a solution to our worlds most pressing challenges as well. Its students and graduates are proof.

Doors didnt just magically open for Thea Baum when she graduated from the university in 2015. It was her qualifications prestige that made the process ever-so-seamless. Recruiters and decision-makers were immediately impressed.

It was relatively easy to find a job after my graduation, she attests. I found a number of job opportunities and I went to a couple of interviews enabling me to make a decision based on the best fitting employment opportunity.

She chose PharmInvent, where she would be able to serve as a Scientific and Regulatory Specialist in the Pharmaceuticals Regulatory Affairs sector and apply all the knowledge and skills she gained as a Masters in Biotechnology student at UCT Prague.

My current position in PharmInvent is strongly related to my field of study at UCT Prague, she explains. The education acquired at the university enabled me to have a good grasp of the technologies currently in use in the biotechnology industry. I am able to understand current EU legislation related to the food, chemical or microbiological industries which helps me consider the regulatory requirements that need to be addressed in pharmaceuticals.

UCT Prague is one of the countrys largest educational and research institutions. Source: University of Chemistry and Technology, Prague

Such confidence is typical of budding changemakers who choose UCT Prague. The theme of sustainability persists across its Faculty of Chemical Technology, Faculty of Environmental Technology, Faculty of Food and Biochemical Technology, Faculty of Chemical Engineering, the Department of Physical Education and Sport, Department of Education and Human Sciences, Department of Languages, and the Department of Economics and Management (also known as the UCT School of Business).

Within them, students can choose from a wide array of bachelors, masters and PhD programmes taught in English. With a student to faculty ratio of 20:1, classes are productively intimate. Hence, curricula are hands-on and ample guidance awaits in state-of-the-art, facility-filled spaces. Essentially, everything one could need to gear up for a future of change-making is ready and waiting. Pathways abound for such outcomes.

Take the MSc in Sustainability and Environmental Engineering, for instance. This programme provides learners with expert knowledge of environmental chemistry, microbiology, hydrobiology, water and atmosphere technologies, decontamination technologies, and waste handling technologies all of which are crucial for tomorrows green heroes.

Its interdisciplinary nature ensures students are comprehensively trained to leverage water technologies and air protection technologies. Additional lessons shed light on industrial toxicology, ecotoxicology, environmental analysis, decontamination technologies, and environmentally-oriented legislation. All of the above develops graduates capable of thriving in the fields of process engineering, research and development, design, as well as production control, among many others.

UCT Prague boasts many state-of-the-art laboratories open to all students. Source: University of Chemistry and Technology, Prague

The MSc in Biotechnology and Food Science is equally impactful a programme designed to produce experts with high-level knowledge in biotechnology, bioengineering and food science, with an emphasis on food quality and safety.

It enhances general knowledge gained at the undergraduate level in biochemistry, organic and physical chemistry, biology, microbiology, food technology and analysis, and the fundamentals of biotechnology and bioengineering. Upon successful completion, graduates are primed to assume high-level positions in biotechnological companies, food production plants, organisations oriented to agricultural commodities, the health care sector or pharmaceutical companies.

Business-focused aspirants easily find their place at UCT Prague as well. Its School of Business houses a Sectoral Management Masters programme that prepares professionals for mid- and top-level management positions in industry, industrial policy, innovation policy, commercial policy and finance. At the same time, it lays a solid foundation for academic advancement or research careers through a PhD. The programme offers two majors: Innovation Project Management and Chemical Industry.

The first option is ideal for students keen on gaining proficiency in Financial Management, Project Management, Process Management or Logistics and Supply Chain Management. Meanwhile, the latter is aimed at those seeking more technical expertise particularly relevant for positions in the chemical, food-processing, fuels, rubber or environmental protection industries.

Anything is possible at a university where graduates have gone as far as developing vaccines in the Czech Republic. To find out how you could make a similar impact, click here to learn more about UCT Prague.

Follow the University of Chemistry and Technology, Prague on Facebook, Instagram, Twitter, and YouTube.

The rest is here:
Global changemakers: University of Chemistry and Technology, Prague - Study International News

Caltech Launches Merkin Center for Pure and Applied Mathematics – Caltech

Concurrent with the commitment to endow the new center, Merkin and the Merkin Family Foundation have provided funds to renovate the eighth floor of Caltech Hall. The reconfigured space, scheduled to open in early 2023, will provide a home for the center as well as a base of operations for the American Institute of Mathematics (AIM), which is relocating from its current headquarters in San Jose, California, to Caltech.

Sergei G. Gukov, the John D. MacArthur Professor of Theoretical Physics and Mathematics, has been named director of the Merkin Center. A member of the Caltech faculty since 2005, Gukov is known for important concepts relevant to string theory, quantum field theory, and pure mathematics.

"Caltech has cultivated extraordinary scholars who think deeply about landmark problems in pure mathematics and collaborate across disciplines," says Fiona A. Harrison, the Harold A. Rosen Professor of Physics and holder of the Kent and Joyce Kresa Leadership Chair in the Division of Physics, Mathematics and Astronomy. "The Institute is also home to a diverse community of researchers who push the frontiers of applied mathematics in areas as wide-ranging as algorithmic economics, computational biology, robotics and autonomous control, and quantum information and computing.

"The Merkin Center for Pure and Applied Mathematics will broaden and deepen the impact of the mathematical sciences across campus."

A Passion for Mathematics

As a physician and health care executive, Merkin has devoted much of his philanthropy to supporting basic science and its translation into medical treatments and cures. His love of mathematics, his undergraduate major, has been another significant thread throughout his engagement with Caltech.

Merkin previously endowed two mathematics professorships at the Institute. These positions, together with the Richard N. Merkin Distinguished Visiting Professorship in Artificial Intelligence, will be woven into the Merkin Center.

Jaka Cvitani, the Richard N. Merkin Professor of Mathematical Finance and director of The Ronald and Maxine Linde Institute of Economic and Management Sciences, is an expert in financial economics who focuses on the intersection between computer science and economics. Nikolai Makarov, the Richard Merkin Distinguished Professor of Mathematics, has worked extensively in complex analysis, which investigates functions of complex variables. This field is fundamental to many branches of mathematics and has applications in the natural sciences and engineering.

Both Cvitani and Makarov will serve as advisers to the new Merkin Center for Pure and Applied Mathematics, together with Elena Mantovan, a professor of mathematics who focuses on arithmetic geometry and number theory.

Mathematics at Caltech

Although small, Caltech's pure mathematics program is expansive in terms of focus and impact. Mathematics scholars at the Institute work together and with colleagues across disciplines to untangle some of the most difficult problems in the field and have garnered high honors for pushing the frontiers of analysis, combinatorics, group theory, mathematical physics, and number theory. They have written texts that are considered foundational to the discipline, and the Institute relies on them to help impart the quantitative skills in which all Caltech graduates become well versed.

Investigators in the Institute's highly ranked Computing and Mathematical Sciences (CMS) department are active in applied mathematics, communication and networks, computer science, and control and systems. Like Caltech's mathematics faculty, CMS faculty are highly collaborative. They have built partnerships with colleagues in mathematics as well as in applied physics, bioengineering, biology, economics, electrical engineering, geology and planetary sciences, mechanical engineering, and physics.

Caltech is also home to a world-leading research center in quantum information and computation. Scholars affiliated with the Institute for Quantum Information and Matter (IQIM) explore the interplay of mathematics, computer science, and physics.

Mathematics is central to the work of faculty and students in numerous other areas across campus, in part due to the sheer amounts of data being collected. Among the researchers who stand to benefit from partnership with the Merkin Center are those working on models of neural processing and brain function, predictive modeling of health care diagnoses, election security, earthquake modeling, "smart" energy grids, and climate models to enable more accurate prediction of droughts, heat waves, and rainfall extremes.

Merkin's Previous Support of Caltech

A member of the Caltech Board of Trustees since 2007, Richard Merkin has supported a variety of initiatives across campus. His previous gifts have created the Heritage Research Institute for the Advancement of Medicine and Science at Caltech, founded in 2015 and renewed in 2018 and 2021, which provides cohorts of Caltech scientists and engineers with salary support and no-strings-attached research funds that free them to pursue high-risk, high-reward projects. Merkin also partnered with Caltech to launch the Richard N. Merkin Institute for Translational Research, which enables scientists and engineers to transform their breakthroughs into advances in human health. Additionally, beginning in 2021, the Richard N. Merkin Start-Up Scholars Grants have provided pre-arrival support to help incoming undergraduates from low-income backgrounds make a successful transition to campus life.

"Richard Merkin is a remarkable philanthropist, making possible fundamental discovery across a broad range of fields and encouraging intersections with the practical," says Caltech president Thomas F. Rosenbaum, the holder of the Sonja and William Davidow Presidential Chair and professor of physics. "Above all, Dick takes joy in making it possible for researchers to thrive, whether they be students, postdocs, or faculty members."

See the original post:
Caltech Launches Merkin Center for Pure and Applied Mathematics - Caltech

Faculty and Students Weigh the Risks and Rewards of SEAS’ Corporate Partnerships | News – Harvard Crimson

Research at Harvards School of Engineering and Applied Sciences spans interdisciplinary academic fields and relies on collaboration with organizations beyond the University including for-profit partners.

While some faculty members and students highlight the benefits of corporate partnerships, others caution working with for-profit entities requires balancing ethical risks and educational rewards.

Ellie Carlough, who heads SEASs collaboration with the private sector, said her position as director of industry partnerships was established by SEAS Dean Francis J. Doyle III, who she said has stressed the value of long-term industry partnerships.

The emphasis of the partnership building is not on raising funds or extra sponsored research funding, although that is certainly an element, she said. The main goals were to build partnerships to support students and faculty.

Carlough said corporate partnerships provide internship and employment opportunities to students, while also exposing them to real-world applications of science and engineering.

She lauded Engineering Sciences 96: Engineering Problem Solving and Design Project as an experiential class that allows students to benefit from the schools corporate partnerships. Students in the course are commissioned to solve a challenge faced by an industry sponsor and receive mentorship from these outside experts.

Samir Mitragotri, a bioengineering professor who taught ES96 in the fall, said he has found SEASs collaboration with industry partners to be educationally rewarding.

It not only provides benefits in the research direction, but also it provides a good educational component to the students, Mitragotri said. A lot of our students, when they graduate, go on to industry, and for them to really have this context as a part of their education I think is quite helpful.

Engineering student Yasmin Omri 24 similarly praised CS 148: Design of VLSI Circuits and Systems. Her professor obtained a partnership with a semiconductor fabrication plant to tape-out the computer chips that she and her peers were designing. She called this partnership motivating for her work.

Had they not been able to secure a partnership with that corporation, I think the learning would probably be more theoretical, she said. Having the actual implementation happen is dependent on having corporate partnerships.

But Mitragotri acknowledged a difference between the interests of scholars and corporations, who must answer to stakeholders.

There is an immediate sense of practicality and utility in industrial engineering, Mitragotri said, whereas in academia, researchers enjoy the luxury of asking very open, futuristic questions.

SEAS professor James H. Waldo said he has previously encountered industry partners who have attempted to dictate what he would report in his research, but he stood his ground.

Making sure you dont fall into the Here, Ive got some money. Go do something for me trap is important, Waldo added.

According to Waldo, SEAS has strong ethical guidelines in place to avoid conflicts of interest, but theres no way really to enforce all ethical questions. He added that researchers have discretion over the private companies with whom they partner.

This is not something for which there is a hard and fast rule, he said. This is something where we have to rely on the good judgment of the academics involved, of the industry involved.

According to University spokesperson Jason A. Newton, Harvards Office of Technology Department puts in place policies to preserve the integrity of research partnerships with corporations. All research agreements developed by OTD set reasonable limits on rights granted to corporate partners and refuse to promise any specific research results, Newton wrote in an email.

The research and any resulting IP are provided to the company on an as is basis, he wrote.

Engineers Without Borders, a student organization, also works closely with corporations, which offer technical support and help further the clubs long-term projects.

Having these corporations and business professionals in our network really helps us bring to reality any sort of ideas that we have, and really learn from them, said Omri, co-president of EWB.

Omri said she hopes the school investigates the social and environmental responsibilities of potential industry sponsors before entering into partnerships.

My hope is that theyre established on ethical grounds, she said.

Staff writer Felicia He can be reached at felicia.he@thecrimson.com.

Staff writer James R. Jolin can be reached at james.jolin@thecrimson.com.

Go here to see the original:
Faculty and Students Weigh the Risks and Rewards of SEAS' Corporate Partnerships | News - Harvard Crimson

SMS grad who lives her passion for STEM rewarded with Fulbright Fellowship – ASU News Now

April 26, 2022

Editor's note:This story is part of aseriesof profiles ofnotablespring 2022 graduates.

Miriam Goras has always been fascinated by simple, fundamental questions relating to how nature works, and during her first semester as a sophomore at Arizona State University she began a research regime investigating the underpinnings of Alzheimers disease. Double major Miriam Goras was recently awarded a prestigious Fulbright fellowship to conduct research in Norway. Download Full Image

I decided to pursue a biochemistry and neuroscience double major because they are research-intensive and I wanted to be able to closely connect the material I learned in the classroom with what I was doing in the lab, explained Goras.

She is about to graduate from the School of Molecular Sciences (SMS) and Barrett, The Honors College with a double major in biochemistry and neuroscience. She has also recently been awarded a prestigious Fulbright fellowship to conduct research in Norway.

Goras has received multiple honors and awards while attending ASU including the 2021 SMS Moeller Award.

This scholarship provides me with the opportunity to get involved in outreach programs for young women who may not have many female role models in STEM as happened to me growing up, Goras said.

As one of ASUs Lincoln Scholars, Goras put into practice her passion for equity in STEM.

She started small by becoming a member of Education for Humanity, where she mentored young female college students in science to help them navigate their way through their college endeavors.

Goras was also named a SOLUR undergraduate research fellow, which allowed her to prioritize her outreach efforts. She has participated in a variety of educational outreach programs to get the younger public excited about recent science and biochemical breakthroughs.

Question: What was your aha moment when you realized you wanted to study the field you majored in?

Answer: I entered college as a biology major I have always been fascinated by simple, fundamental questions about how nature works. The fall semester after my first year at ASU, I joined Professor Paul Colemans lab at the Biodesign Institute. Much of my interest in biochemistry and neuroscience as a field stemmed from what I was learning in the lab investigating the underpinnings of Alzheimers disease. I later decided to pursue a biochemistry and neuroscience double major because they are research-intensive and I wanted to be able to closely connect the material I learned in the classroom with what I was doing in the lab.

Q: Whats something you learned while at ASU in the classroom or otherwise that surprised you or changed your perspective?

A: A valuable lesson that I learned during my time at ASU is that as a scientist, my values and subjectivity inevitably affect my work. However, taking part in ethical discourse will allow me to become aware of my personal biases and identify gaps in my ethical decision-making process in research. Thinking critically about ethical norms will prompt me to examine the aims of my research and determine my responsibilities as a researcher. Recognizing that scientific progress is rooted in creative ethical inquiry, I believe that having my perspective challenged will strengthen the connection between discovery at the bench and innovation in the real world.

Q: Why did you choose ASU?

A: I chose ASU because of the limitless resources and opportunities available, ranging from access to expert faculty to potential scholarships and impactful activities. The culture of diversity and inclusion at ASU encourages growth through cooperation and support. Therefore, I knew coming here would allow me to thrive and develop as an individual and future professional.

Q: Which professor taught you the most important lesson while at ASU?

A: Its difficult to narrow it down to just one professor and one lesson because of all the amazing professors I have had at ASU, but I will mention three of them. Professor Susan Holechek taught me the importance of mentorship, especially as a female in STEM. Of not only having a mentor who supports your goals and wants you to thrive but also serving as a mentor for others and uplifting those who were in the same shoes as you when you started. Professor Scott Lefler of SMS taught me perseverance through some of the most difficult college courses Ive taken at ASU. Professor Samuel McClure taught me the value of pursuing your passions. His enthusiasm for the course subject and for teaching clearly comes through, which is inspiring.

Q: Whats the best piece of advice youd give to those still in school?

A: My best advice is to spend time exploring. I took Spanish/Chicano literature courses, dance classes and even graduate seminars, all of which enriched my experience at ASU. There are so many amazing classes at ASU, it is important to take advantage of them.

Q: What was your favorite spot on campus, whether for studying, meeting friends or just thinking about life?

A: My favorite place to study on campus is Hayden Library on the second floor. Nothing beats studying by windows where you can enjoy a beautiful view of campus or watch the sunset at night.

Q: What are your plans aftergraduation?

A: I have recently been awarded a Fulbright fellowship to conduct research in Norway and was accepted into the interdepartmental graduate program at Northwestern University to pursue a doctorate in neuroscience. I will do both, because Northwestern gave me permission to defer my enrollment until after I complete the Fulbright work.

Q: If someone gave you $40 million to solve one problem on our planet, what would you tackle?

A: I would spend the money on efforts to make education more accessible and equitable. Everyone should have access to high-quality education regardless of income, gender, location, race or background. Through equitable education, you empower more people to become critical thinkers and problem solvers who apply their knowledge to complex and novel challenges.

Read the rest here:
SMS grad who lives her passion for STEM rewarded with Fulbright Fellowship - ASU News Now

Tackling chemical synthesis and advocacy | MIT News | Massachusetts Institute of Technology – MIT News

Azin Saebi was born and raised in Iran, emigrating to the U.S. with her family at 18 after graduating from high school. Now a fifth-year graduate student in chemistry, Saebi never intended to stay permanently; she initially expected to go back to Iran to attend university. With that in mind, when leaving for the U.S., she only packed a bag with enough belongings for a couple of months and had even booked a return flight.

Her plans changed, however, as she began to recognize the opportunities available to her at American colleges, and that the best way to improve her English would be to stay in the U.S. Since she hadnt taken the SAT or completed the requirements necessary to enter a traditional four-year college, she enrolled in community college with a plan to study biology and neuroscience, before transferring to UCLA.

In community college, Saebi discovered that she loved her undergraduate chemistry courses, so she joined an inorganic chemistry lab. I really clicked more with the day-to-day lab experiments in chemistry rather than biology. It was fun and exciting how I could take material A and material B, mix them together in a controlled way and get this new molecule, she says. To her, biology seemed like more of a black box. With chemistry, I could check the progress at every step along the way.

At MIT, Saebi is working at the intersection of chemistry and biology, designing novel strategies to synthesize proteins and to conjugate proteins together. Ultimately, these strategies have potential applications as antimicrobial compounds. In addition to her academic pursuits, she has devoted her time to advocating for diversity and inclusion initiatives and ensuring that students feel supported and heard within the chemistry department.

Lighting a fire of chemistry

When she started at Saddleback Community College, Saebi first chose to pursue a degree in neuroscience, with the intention of becoming a physician a path influenced by watching Greys Anatomy, she jokes. Taking organic chemistry also sparked an interest in the interface between chemistry and biology. A biochemistry course at UCLA further cemented this passion, and she found that she excelled in the subject. It was rather obvious that among neuroscience majors, [my reaction] to the class was an uncommon one, as it was generally considered a pretty irrelevant class to our core studies, she says.

Saebi decided to double major in neuroscience and biochemistry. An inspiring professor, Alexander Spokonyny, encouraged her to join his inorganic chemistry lab. He was the person that lit this fire of chemistry in me, she says. Under his guidance, she synthesized small-molecule inhibitors to study cocaine addiction.

In the fall of senior year, Saebi knew that she wanted to pursue this research thing and that her interest in medicine had taken a back seat. She decided to enroll in UCLAs 4+1 program to complete a masters degree in biochemistry before applying to graduate programs in chemistry.

Unleashing novel proteins and inner nerds

When Saebi was admitted to MIT, she was determined to take advantage of the opportunity. Growing up in Iran, I never imagined I would have the opportunity to go to a world-renowned university such as MIT, she says. During the chemistry departments visit weekend, where admitted students are invited to come to campus, she realized that students here actually looked like me in terms of the science they loved and the activities they were involved with.

Since beginning her PhD, Saebis aim has been to transition from organic chemistry to chemical biology. Even though I enjoyed doing organic chemistry, I really wanted to pursue something with direct applications, she notes. With this in mind, she decided to affiliate jointly with the labs of professor of chemistry Bradley Pentelute, and with Stephen Buchwald, the Camille Dreyfus Professor of Chemistry. The Buchwald lab focuses more on the organic chemistry methods, while the Pentelute lab focuses on peptides and emphasizes biological applications. I really enjoyed making molecules, but I also knew that that alone would not keep me satisfied during the five years of my PhD, Saebi explains. I needed to make sure that I made something that I could apply to the biotechnology industry or to human health.

The overall theme of Saebis work is developing novel chemical tools to modify biomolecules, specifically proteins. Her research has evolved in three distinct stages. First, she investigated a novel bioconjugation strategy, a chemical technique used to couple two proteins together. Then she worked on a method of synthesizing proteins via chemical ligation of amino acids, relying on chemical techniques to join the amino acids together instead of biological protein synthesis machinery. Most recently, Saebi has been combining these two tools, bioconjugation and chemical protein synthesis, to make antimicrobial compounds that specifically target and destroy Pseudomonas, a bacteria that can lead to serious infections in hospital patients.

Outside of lab, Saebi has served as a teaching assistant for course 5.07 (Introduction to Biological Chemistry). It turned into a fun experience of helping [undergraduate] students unleash their inner nerd, Saebi notes. Given that I had really enjoyed my biochemistry classes back at UCLA, I really wanted to make sure that my students had the same experience. She had to overcome her fear that, since English is her second language, students wouldnt understand her explanations. Despite her initial hesitations, Saebi won the Department of Chemistry Outstanding Teaching Award in 2018. For her, that was the cherry on top of a rewarding teaching experience.

Sparking change for graduate students

In the past two years, Saebi has become an advocate for diversity, inclusion, and speaking up about challenges within MIT, serving as a member of the chemistry departments Diversity, Equity and Inclusion Committee (DEIC) and co-president of Women+ in Chemistry (WIC+). Over time, Saebi has realized that one of her personal strengths is communicating student needs, a skill she has leveraged in these leadership roles.

Graduate school is hard, and nothing is going to make it an easy-breezy experience because science is inherently hard. But, there are things that can make graduate school a bit easier and a more enjoyable experience. Often we have the attitude that we will just suffer through it just because others before us have suffered through it, and thats a problem she says. Saebi is not content to just suffer through it; instead, she is determined to be the spark for change.

She is most proud of the holistic review of graduate admissions practices drafted by DEIC and implemented in chemistry admissions this year. The new practices evaluate candidates based on opportunities available to them, and their potential for growth, as well as their accomplishments.

She also serves with Resources for Easing Friction and Stress in the Chemistry Department (ChemREFS), which offers students an avenue to speak confidentially about their problems and to receive support. Learning about her peers struggles has informed her role in the DEIC, she says. ChemREFS is helpful to me to ensure that I am actually representing the student body and the diversity of voices and perspectives.

As she nears graduation, Saebi has been considering her next steps. She wants to continue solving problems in human health, and she understands that it can be a challenging and lengthy process translating academic research to new treatments for patients. I want to be somewhere that I can see the impact of my work on patients lives and health care more immediately, and Im grateful that my PhD at MIT has opened so many doors for me to explore science beyond academia, she says.

See more here:
Tackling chemical synthesis and advocacy | MIT News | Massachusetts Institute of Technology - MIT News

Too much Anatomy and Biochemistry, Instagram better than textbooks on sexual and gender minorities Jamia Hamdards Dr Aqsa Shaikh wants to change…

On April 15, Dr Aqsa Shaikh, a self-proclaimed queer activist, teacher of community medicine at Jamia Hamdard and nodal officer of a COVID vaccination centre, sparked a controversy by saying that the medical curriculum in India teaches too much Anatomy and Biochemistry. Dr Aqsa also claimed heterosexual doctors should not teach about queer lives. Furthermore, she said, Instagram teaches more about sexual and gender Minorities than textbooks. Her statement attracted strong criticism on social media.

In a series of tweets, Dr Aqsa mentioned the points she had raised during a panel discussion on making Medical Curriculum queer affirmative at AIIMS. She said the fraternity should stop medicalising queer identities. Furthermore, she claimed that the Indian medicine curriculum is teaching too much of Anatomy and Biochemistry. According to her, 5.5 years were not enough to learn about health.

Dr Aqsa demanded that Medical Science should be turned into a Bachelor of Health and the students should be taught subjects of humanities with medicines. She said it is time to reverse Millers Pyramid, Empathy should be the base, not Cognitive domain. She claimed the CBME (Competency Based Medical Education) curriculum is flawed and suggested that doctors should be political.

Interestingly, she added that Heterosexual people should not teach about queer lives and demanded more marginalised communities should be brought in as teaching staff. According to Dr Aqsa, the current Transgender Act has many anti-queer laws, and it needs amendments. The education about queer should begin at the primary level and not at medical school. One of the most controversial statements she made in her tweets was that Instagram taught more about sexual and gender minorities compared to the textbooks.

Her statement has attracted sharp criticism, especially from the Medical community on Twitter. Dr Lira questioned why such discussions were even allowed by AIIMS. She said, From where is this irrational thinking seeping into #medical system? Why is AIIMS even allowing this? Medicine is pure Science unadulterated by Identity politics, religion and superstitions. One can practice medicine with basic human decency without needless affirmation.

Dr Pranay said, First, it made me laugh. Then I realised she was serious. Not just a tweet, but this was rather a panel discussion at AIIMS. Im worried now. Ridiculous is too small a term for this.

Dr Apporva Verma said, Too much anatomy? Seriously? While I get 1st point, Id like to know this persons qualification to have uttered such statement as the 2nd point.

Speaking to OpIndia, Dr Haryax Pathak said, While the issue in the hand of LGBTQ rights and awareness is a genuine one, there has to be a systematic approach towards it. It starts by educating people. The biology behind it. The history behind it. That means more Anatomy, more Biochemistry not less. Training empathy is required, but it is a slow process. Im against the claim that doctors must be political. I can have political preferences as an individual but they dont reflect in my professional life. Doctors dont differentiate or discriminate on a political basis.

He further added, Claims that Instagram teaches more than medical school are way harmful. There has to be a professional approach to medical education. Ironical that slurs of WhatsApp University are passed around while promoting Instagram education. He agreed there was a need for some legal amendments as transgenders are humans too, and they have rights equal to everybody else.

Originally posted here:
Too much Anatomy and Biochemistry, Instagram better than textbooks on sexual and gender minorities Jamia Hamdards Dr Aqsa Shaikh wants to change...

Board of Visitors summary of actions and discussions – James Madison University

The James Madison University Board of Visitors met Friday, April 22, 2022 in the Festival Conference and Student Center.

The following is a summary of actions taken by the board and key areas of discussion at the board meeting:

Approved the February 18, 2022 Board of Visitors meeting minutes and the personnel action report;

Accepted committee reports from the Academic Excellence, Advancement and Engagement, Athletics, Audit, Governance, Finance and Physical Development, and Student Affairs committees;

An update on the General Assembly was provided by Caitlyn Read, Director of Government Relations;

The 2022-23 proposed tuition and fees and the proposed 2022-23 budget was presented by Towana Moore, Interim Vice President of Administration and Finance;

A reaffirmation of the Universitys mission statement was presented by Brian Charette, Special Assistant to the President;

A racial equity and diversity, equity and inclusion update was provided by Deborah Tompkins Johnson;

Tim Miller, Vice President for Student Affairs led an update on COVID-19;

The Board of Visitors voted to approve the proposed 2022-23 proposed tuition and fees, the 2022-23 proposed summer tuition and fees and the proposed 2022-23 budget, pending the outcome of the state budget;

It was voted by the Board of Visitors that the University reaffirm the current mission statement;

The Board of Visitors voted for the next Rector of the Board to be Maribeth Herod, Vice Rector to be Chris Falcon and Secretary of the Board Donna Harper.

President Alger shared during his Presidents Report:

Link:
Board of Visitors summary of actions and discussions - James Madison University

The Future of Longevity is Now: How to Live and Lead to 100 – Thrive Global

For many (albeit not all) the future of longevity is now; we are already living longer. According to the U.S. Census Bureau, the number of Americans living into their nineties is expected to quadruple by 2050. Demographers predict that as many as half of todays 5-year-olds can expect to live to the age of 100 in the United States. A century-long life will be a reality for more and more of us, so Id argue that anyone who equates increasing age with decreasing quality of life (and contribution!) read on and discover how to activate your potential leadership and impact. No generation before us has had the potential to experience the benefits of increased longevity, sustained vitality and the capacity to consciously curate decades of a meaningful life.

The Stanford Center for Longevity (SCL) has done extensive and exciting work in this very area. With breadth of cross-disciplinary research and ongoing data collection, SCL addresses the how question at the meta-level looking globally and structurally at policy and infrastructure changes necessary to support our longer lifespans in equitable ways. SCLs recently published The New Map of Life navigates us toward new models of all the nitty-gritty things that will need to be updated and radically shifted: education and lifelong learning; redesigning how we work; developing new policies for health care, housing, the environment, and financial security. Im proud to support the big picture shifts that need to happen through my involvement on the SCL Advisory Council. All of us are stakeholders and leaders, from wherever we are, in the seismic shifts outlined by The New Map of Life.

Both the New Map of Life and my formula for a life well-lived share an understanding that longevity is not simply a measure of the quantity of years or Lifespan, but it is about the quality or Healthspan of those years. A burgeoning medical specialization known as Lifestyle Medicine is the systematic practice of assisting individuals and families in adopting and sustaining behaviors that can improve health and quality of life. Were all familiar with the idea of preventative care, so why is it significant that our tradition-bound medical system has developed this new area of study and practice? Its not only because five of the seven leading causes of death in the US can be attributed to chronic, lifestyle-related conditions. Lifestyle medicine recognizes that your physical health, emotional wellbeing, and the accumulated effect of your daily lifestyle choices are inextricably linked.

Health and wellness has become a multi-trillion-dollar industry, with estimates reaching over 8 trillion in just a few years. With everything from Pelotons, FitBits, supplements, fad diets, and far too many other options to mention, embracing responsibility for your health while sifting through the massive information available can feel daunting and is often unnecessarily expensive. However, cultivating your health and wellness doesnt require expensive participation in that behemoth industry. Chinese philosopher Lao Tzu once said, a journey of a thousand miles begins with a single step. Your health and wellness journey can start today, and Im here to simplify it. In the Five to Thrive process, I unpack the building blocks that ancient traditions and modern research agree bolster your health and wellness. Take the free assessment from which you can create your own micro-ambitious plan.

As our recent Facebook quiz taught us, what makes a 100-year life worth living is when it is imbued with an ability to remain independent, with a sense of community, meaning, purpose and joy. To me, the discussion of longevity boils down to this: a life well-lived is not only measured by the number of healthy years you live but by whether or not you thrived in those years. And as social scientists from Victor Frankl to Brene Brown have proven time and again, without a sense of purpose and a capacity to love and be loved, we fail to thrive as humans.

Purpose and the deeply catalyzing force of love ground and propel every single one of us. Purpose, love and connection are central to my work as a leadership coach and a consistent element of what separates the good from the great. So, if we consider any formula for longevity seriously, a sense of purpose and love that bring meaning to this thing called life are required ingredients. You can cheat on a diet, you can get away (for a while at least) without daily exercise, but you cant shortchange your spiritual and emotional health for long without serious consequences.

Resilience is the bounce-back factor, the capacity to prevail in the face of stressors outside your control. Resilience means aiming for a sense of realistic, holistic alignment that is not contingent on your body being perfect or pain-free, unmarred by time, but extends beyond the physical and mental, and into spiritual wellbeing as well. Its so challenging to cultivate resilience in light of the diet of success stories and routes to that success which weve been fed since our childhood. It goes like this: study hard, work harder, make the right connections, prove yourself, do it again. The underlying expectation has been that this recipe will cook up a smoothie of success for life. Yet, life is not a linear path towards ever-ascending destinations. Its a journey that unavoidably hits detours through mountains and valleys. Those of us who understand and regularly practice strengthening our physical and psychological resilience are those with the right ingredients for a life well-lived. So yes, if were talking about living toward 100, resilience will be required. Lots of it!

I love the way the Stanford Center for Longevity frames aging as a longevity buffet with servings of time. This begs for the question: what are you hungry for? Ignore the ageist memes and other cultural tropes that result in our missing out on the wisdom of our elders and suffering for that loss. You are needed now, perhaps more than ever. What the world needs now is not only love, sweet love, but wisdom, courage, experience, and a spirit of wanting to do the right thing for the sake of simply doing the right thing.

Originally posted here:
The Future of Longevity is Now: How to Live and Lead to 100 - Thrive Global

The lowdown on longevity – Health Report – ABC News

Norman Swan: Hello, Norman Swan here with this week's Health Report. Life expectancy has been rising about three months a year since the mid 19th century. We do well in Australia and are usually in the top five or six most long-lived nations. When we personalise this to the individual although, life expectancy, which is a national average, becomes irrelevant. What many of us really want to know is how long we are going to live and how much of that will be in good health. Living longer is an obsession and there are pills galore being offered to slow ageing and maybe even reverse it. Even so, the increase in longevity may be stalling, and you've heard a lot about that on the Health Report over the last two or three years because our metabolic health is declining and our abdominal girth is increasing.

So what works in slowing ageing? Well, that's been the life work, at least so far, of Luigi Fontana, an international authority on the biology of ageing and the dietary interventions, especially calorie restriction, which in fact is what many of the anti-ageing pills seek to emulate without having to cut back on what you eat. Luigi Fontana is Professor of Medicine and Nutrition and has a chair in translational metabolic health at the University of Sydney, and I spoke to him recently at length.

Luigi Fontana: When I was a medical student we had a professor in geriatrics who gave a very interesting lecture about the effects of dietary restriction in mice being the most powerful intervention to extend lifespan and health span. And so I was fascinated. I said, ah, so there is something in mammals that is able to extend lifespan up to 50%. It is like for human beings instead of living 80 years, to live 130, 140 years. The data back then, so we're talking about 25 years ago, were showing also a huge increase in health span with the prevention of cancer, cardiovascular disease and kidney disease, autoimmune diseases

Norman Swan: And before you go on we should just define our terms here. So, lifespan, just crudely, is how long you live, it's not life expectancy, it's just the absolute number of years you have on the planet, and health span is how many healthy years you've got before disability and other diseases start to encroach on your life.

Luigi Fontana: Absolutely. I wasn't happy with being a practitioner where you go to the emergency room because there is a patient with a myocardial infarction, a stroke, and you try to minimise the damage. I said, is it possible to understand if humans, like animals on calorie restrictions, they live at least healthier and possibly longer if we can slow down ageing and accumulation of damage? And so I started to search and there was nothing in humans

Norman Swan: And the important caveat here isit's bloody obvious when you think about it, but mice are not humans, although dietary restriction does spanthey've shown it in fruit fly, in yeast, in other animal species.

Luigi Fontana: In monkeys now, rhesus monkeys.

Norman Swan: But the holy grail is humans because humans are a lot more complicated.

Luigi Fontana: Just to give you an example, mice or rats, they live on average 2.5 years, human beings live on average for 80 years. Rhesus monkeys, they are primates, they live on average 26, 27 years. So even if they are primates, they live a third of what a human being nowadays lives. And so basically I decided to search and I discovered that there was a Professor John Holloszy in the US at Washington University who was starting a program on calorie restriction in humans, and he replied to me and said, come on, come to the US. So I took my luggage and then I fell in love with what I was studying. John, he just died a couple of years ago, was one of the guys who discovered that exercise increases mitochondrial biogenesis, is improving insulin sensitivity, preventing diabetes. So he was a brilliant mind, a pioneer.

Norman Swan: And we will come back to mitochondrial biogenesis in a minute because these are the energy sources in the cells, possibly the source of ageing, and regenerating, revivifying these mitochondria might be one of the answers for delaying ageing.

Luigi Fontana: Exactly. And I spent the next 17 years working on humans, research on calorie restriction. So we studied people who were practising calorie restriction, so what is called technically a cross-sectional study, you compare these people with people who are master athletes or sedentary men and women consuming Western diets. And then we did two big randomised clinical trials, the calorie where we randomised people on calorie restriction. The first one, the step one calorie randomised clinical trial was comparing people randomised to 25% calorie restriction without malnutrition, so with all the vitamins and minerals.

Norman Swan: So what with the outcomes you were looking for, because you can't hang around for 90 years to see whether or not they live longer.

Luigi Fontana: Exactly, so lifespan is impossible. Even in monkeys, the monkeys study now we have finished 20 years to get data on survival, and so it's feasible but for humans it's impossible. In terms of longevity what we are trying to do is to develop biomarkers of ageing, what is called biological ageing, can we measure biological age and with some biomarkers. Right now the most common one, the most trendy one is epigenetic ageing. So you measure DNA methylation, and there are some DNA methylation clocks that are

Norman Swan: So, just to explain, epigenetic changes are not mutations in the actual DNA, they are chemical reactions around the side of the spiral, the helix, which changes its shape and changes its function. And this DNA methylation that you are talking about is one of these chemical reactions that changes the shape, for better or for worse.

Luigi Fontana: Yes, exactly, and so basically these epigenetic changes is basically the regulation of which part of the DNA is translating into proteins. And what we have discovered is that what you do in your life, what you eat, if you exercise, if you smoke, if you are stressed, is changing the transcription of DNA. And new data is suggesting that as you age, basically there are changes in this transcription

Norman Swan: Which may well measure your clock as opposed to how many days or months you've been on the Earth, it's really how many days or months it affects your biology.

Luigi Fontana: Exactly, you can compare basically your chronological age, how many months and years you've been living, compared to the biological age. So you can be biologically younger. Let's say you are 50 years old, biologically you are 40, or biologically you are 60. And so these are experimental tools that we are training, that we are working on, and it looks like they are good. And so ideally we hope that in the next few years we are going to refine these biomarkers of biological age and then we can do an intervention, it can be exercise, it can be diet, it can be a supplement, it can be a drug, and we can say, okay, your body has rejuvenated. Or if you are smoking or if you have other unhealthy lifestyles, you have been getting older than your chronological age.

Norman Swan: And what about the telomeres? We've spoken about that a lot on the Health Reportby the way, you are listening to the Health Report on RN with me, Norman Swan, and I'm speaking to Professor Luigi Fontana, world authority on ageing, slowing ageing, the biology of ageing. So we've spoken about the telomeres, these bits on the ends of the chromosomes, almost like the plastic bits on your shoelaces, to protect the chromosomes which get shorter as you age, as each cell goes, and also if you seem to have less damage of ageing they seem to be longer. Are they good as markers for ageing?

Luigi Fontana: Look, we don't use them in our research. In the past there was a lot of hope that good biomarkersbut Elizabeth Blackburn who got the Nobel prize for telomere and telomerases, she is a friend, and I sent her some samples of these people doing calorie restriction, and we don't see changes. And even in animals on calorie restriction we are not able to use those as a biomarker. It doesn't mean that what you just said, that as you age, every time the cells are dividing or replicating the telomere gets shorter. So, no doubt about it, it's real. I'm just saying that

Norman Swan: It's not a good clock.

Luigi Fontana: Exactly.

Norman Swan: So, come back to the trials now; what do the trials show?

Luigi Fontana: So the first one we compared people who were doing 25% calorie restrictions without malnutrition, or people who were exercising to increase their energy expenditure by 25%, and then we had the control sedentary group. And we found that of course they were leaner, they had less visceral fat. Interestingly, both the CR and exercisers lost around 9% of their body weight, and 40% on average of their visceral fat.

Norman Swan: The dangerous fat in your tummy.

Luigi Fontana: Yes, the dangerous abdominal fat. And then we found improvements in inflammation, reduction of inflammation, we found improvement in insulin sensitivity.

Norman Swan: And just again, so inflammation, which is really an overactive immune system which causes thickening and damage to your internal vessels, is probably part of the ageing process.

Luigi Fontana: Yes, inflammation now we know is a key factor in the development of cancer, cardiovascular disease, stroke and many other diseases, including ageing. So it's one of the major players in ageing and many chronic diseases. So we saw an improvement in insulin sensitivity. Insulin is very important, based on many animal models of longevity. So nowadays we can play with genes and we can knock down one gene or we can over-express one gene in rodents, and then we can look at what are the physiological or lifespan effects of these genetic manipulations. And so I will say that 80% of the animal models of longevity, meaning mice that are living longer than the wild type, they have a mutation in the insulin IGF-1 pathway, so they have less insulin biding, less insulin transduction. And what we know is that as you get older, especially as you accumulate belly fat, visceral fat because you are in a positive chronic energy balance, you are becoming insulin resistant. So there are a number of hormones produced by the adipose tissue called adipokines that are making the skeletal muscle but also the adipose tissue and other cells resistant to the effects of insulin.

Norman Swan: And you get growth hormones that can stimulate cancer, so a lot of focus is on insulin, it's much more than diabetes in terms of how it affects the body.

Luigi Fontana: Yes, a lot of people think about insulin when they talk about diabetes. In reality, before you become diabetic you have many years of insulin resistance and hyperinsulinaemia. So the beta cells of the pancreas that are the cells that are producing insulin, they are trying to over-produce insulin to overcome the peripheral insulin resistance, and this hyperinsulinaemia is driving cancer and ageing.

Norman Swan: So, high levels of insulin.

Luigi Fontana: Yes.

Norman Swan: So you've got a signal that reducing calories by 25% seem to be doing similar stuff to

Luigi Fontana: Exactly, so if we have to summarise what we did find, many of the metabolic hormonal adaptations that we have described in long-lived dietary restricted animals are also occurring in humans. So humans are adapting to calorie restriction similarly to animals. Another important one, we found a major reduction in oxidative stress markers, biomarkers like F2-isoprostanes.

Norman Swan: This is biological rusting, which goes along with inflammation and drives those mitochondria that we were talking about as well.

Luigi Fontana: We also saw an increase in autophagy proteins in genes. Autophagy is another important mechanism.

Norman Swan: So again, to explain, your cells get old and they should die but some cells don't die and they just sit there causing havoc and you want the body to get rid of them

Luigi Fontana: But that's senescence. Autophagy is different. So as we get older, we have accumulation of garbage in our cells because our cells are becoming less efficient to remove misfolded proteins, old mitochondria, so mitochondria that get oxidised, they become dysfunctional, and so if you are in energy restriction, the cells, they are trying to say, okay, now where do I get the material to create energy for cell functioning, and they start to digest the garbage, and so that's called autophagy.

The other factor we found in humans as well is what you are saying before, cell senescence. As we get older, we have an accumulation of DNA damage, and when you have accumulation of DNA damage that can be stimulated by smoking or radiation and many other stuff, you have two different options. One is this DNA damage ends up in oncogenes, you have cancer. Otherwise, this DNA damage can cause cell senescence. And what other colleagues have found is that these senescent cells, these old cells, these zombie cells, they are producing pro-inflammatory cytokines. So this is a major source of inflammation itself. They are also secreting pro-cancer factors, and we found that in humans and in animals on calorie restriction, there is a reduction in senescent cells.

Norman Swan: So, popular books out there being sold as the solution to ageing, and I'll declare a conflict of interest here as I've got one coming out in August, but hopefully reasonably scientificlet's just take fasting. So, fasting has been touted as the answer here, and what they do is they say, look, if you look at fasting in animals it prolongs their lifespan, it emulates dietary restrictions. So if you look at the chemical pathways, I'll just use some technical terms like SIRT1, they recapitulate that and work in the same way. So what's your view on fasting as a surrogate for dietary restriction?

Luigi Fontana: The story of fasting, really at least the commercial part, started with the Michael Mosley documentary Eat, Fast and Live Longer, I was one of the two characters on the documentary, and he came and interviewed me in St Louis and then he interviewed Valter Longo in Los Angeles. And back then he put together a nice story, but without scientific data because there were no human studies. And even right now, the data on the effects of fasting, intermittent fasting or time restricted feeding in humans, the data are very, very slim. I'm talking about humans. In animals, yes, the data are overwhelming that intermittent fasting is extending lifespan and health span.

Norman Swan: But isn't there evidence in humans and larger animals that it increases ageing, speeds it up?

Luigi Fontana: No, but we have dataI shouldn't talk about it but I'll give you justwe have a paper submitted now in a major journal for publication, and we were able to do intermittent fasting for six months plus six months, and we see a beautiful reduction in body fat, in body weight and body fat, 8% weight loss, so it's very good for the standards of calorie restriction, but we don't see improvements in inflammation, no improvement in inflammation, a very tiny improvement in insulin sensitivity in many factors. So despite the fact they lose the same amount of body weight that we achieve with classical calorie restriction or with exercise, metabolically we don't see the same responses. Why? Well, what we are finding is that a calorie is not a calorie, that the quality of the food you are eating influences the metabolic response to weight loss, okay? So the shortcut that many think, okay, you know

Norman Swan: So if you're having bacon and eggs, it's not the same as a Mediterranean diet.

Luigi Fontana: Exactly. It's a balance between exercise, the amount of calories you are burning and the metabolic adaptations that you are triggering with exercise, the quantity of calories and the quality of those calories, they are three pillars. Before we were discussing about these easy-fix types of books or solutions that are very, very trendy, it's like if you go to the director of a symphony orchestra and you say, 'Tell me, what is the most important instrument in the symphony?' I don't know, he likes violin or cello. Okay, now I create an orchestra only with violin

Norman Swan: It's funny you should say that, actually one of my chapters in my book says anti-ageing is orchestral.

Luigi Fontana: Exactly, we agree. So to have a beautiful symphony, I don't know if you like Shostakovich, whatever symphony, or Mahler or Beethoven, you need a balance of all the instruments. If you have an overwhelming violin section, then you kill the beauty.

Norman Swan: So then this translates to the individual substances that people say can influence the pathway like resveratrol or NAD boosters, Fisetin and so on, they should work but they don't when you actually study them.

Luigi Fontana: That's what is coming up, that basically in experimental animals some of these molecules, not the ones you mentioned but, for example, rapamycin and others, they are extending lifespan, but we know, for example, that rapamycin in humans is causing type 2 diabetes, is causing immune depression. So if you are mice who are living in a pathogen-free facility, well controlled, in an environment where you are not exposed to viruses, to bacteria, then it may work. But if you are living in an environment like we do, where there is Covid and influenza and bacteria, then you know some of these molecules are dangerous.

Norman Swan: One of the things I'm interested in is the concept of homeostasis. So homeostasis, just to explain to the audience, is this balance. You talk about the balance in the orchestra and you talk about rapamycin, which is a fascinating substance discovered on Easter Island and taken back and having all these effects and used in people with kidney transplants to stop rejection and so on, is that when you look at ageing, some people would argue that ageing is a disruption of homeostasis, so we have a balance, and the balancesay we don't eat well, we don't get much exercise, we put on weight, the balance just tips towards ageing. So it's like the leaning Tower of Pisa, to use an Italian metaphor. So you have this leaning Tower of Pisa, and then what happensso I'm putting a hypothesis to you, is that when you try and correct the leaning Tower of Pisa to vertical, the whole body wants to push it back to a leaning situation because the body knows it needs a balance. If you are laying down protein and making substances, you've also got to break it down. If you put down fat, you've got to be able to lift it up and use it for energy. And so it's very hard to shift that balance. Does dietary restriction restore the disrupted homeostasis of ageing, so, in other words, the leaning Tower of Pisa?

Luigi Fontana: It looks so, even if the sooner you start calorie restrictionso the classic experiments shows that if you start dietary restriction without malnutrition, and let me reinforce that, 'without malnutrition', so going back to the day of fasting where people say, okay, I fast a couple of days per week and five days a week I eat whatever I want. That is dietary restriction with malnutrition. But in the experimental models we found that if you start 30% dietary restriction in a very young animal, typically we were starting in post-weaning mice, you have an extension up to 50% of lifespan. If you start the same 30% dietary restriction in a 12-month-old mouse that is equivalent probably to a 40-, 50-year-old human being, you have a 15%, 20% increase in lifespan because in those 12 months that is like 40 years for a human being, you have accumulated damage. And yes, you can undo some of the damage but not all of it.

So the message is that at any age you can improve your health by exercising, changing your diet, counting your calories, controlling your calories, the quality of what you eat, but you cannot go back totally to the same effects of when you started calorie restriction when you were younger. So the message is that the sooner you start to counteract the damaging effect of ageingbecause, as you said, ageing is a mechanism where the repair mechanisms are getting old. When you were young you have a bone fracture and you're going to repair very quickly, when you are 70 years old you have a bone fracture, you are not repairingif you have a scar when you are young, you are able to repair very quickly the scar, and when you get older, less, because all these mechanisms, this autophagy, DNA repair mechanisms, the antioxidant mechanisms, the removal of senescent cells, they get old and less efficient to keep homeostasis.

Norman Swan: But there is still an effect.

Luigi Fontana: There is still an effect. What I'm saying is that your trajectory of ageing is the deterioration of 20% of these mechanisms per year. If you eat unhealthy, if you have excess belly fat, if you are not exercising, if you are smoking, if you are over-drinking, you are accelerating the accumulation of damage and the deterioration of these mechanisms instead of if you are exercising, you are eating well, you are eating good quality, you are eating the right amount of calories, you don't gain too much belly fat as you get older, you are decelerating these mechanisms and in some cases you are rejuvenating cells.

Norman Swan: So do you live in a monastic lifestyle then?

Luigi Fontana: No, I think it's noteverything dependsfor example, I exercise I would say one hour, probably 5 to 6 times a week, and here in Sydney it's beautiful because the weather is so nice all year long, that even in the winter, even at 6pm I take my bike and I go for an hour and for me it's refreshing. After one day using my brain, going on a bike, it's beautiful. So, one hour a day out of 24-hours is not a lot.

And then I eat a very healthy Mediterranean diet, so very colourful, very tasty, with a lot of fresh fish and here in Sydney we are blessed, lots of different types of vegetables, whole grains and beans, so I have a range ofI think my diet is more diverse than many Australians and Americans because I have a lot of different recipes, very tasty. So I control my calories in two or three ways. One is to eat a lot of unrefined food, so whole grains and beans and vegetables and fish, and in this way you are already controlling your calories. We did a study in the USagain, we haven't published it but I'll give you the results, we are writing the manuscript right now, where we fed people in a randomised clinical trial for two months a Mediterranean diet comprising basically whole grains and vegetables and beans and fish, poultry once a week only, for two months. But I asked my dietician to clamp the body weight. So if the participant was, let's say, 80 kilos at baseline at the beginning of the study, I wanted the same person to be 80 kilos at the end of two months on this Mediterranean diet, you know, we provided the food.

Norman Swan: So they could see the pure effect of the diet rather than weight loss.

Luigi Fontana: Exactly, the results are going to be striking. But just to tell you the results, we had to over-feed people 250 calories to keep their body weight constant.

Norman Swan: You're kidding!

Luigi Fontana: Yes, and it was designed to be iso-caloric

Norman Swan: So it's hard work to maintain the weight.

Luigi Fontana: It was hard work, they were losing weight like crazy because the high-fibre diet compared to their typical American super-refined ultra-processed food, it was already able to make them lose weight like crazy. So this is a simple trick. You think about calorie restriction like, you know, having these tiny portions, an empty plateno. I'm eating huge amounts ofif you look at my plates, huge and big salads, very colourful, tasty, I do my dressing with orange juice or lemon juice with pepper and this and that, a lot of spices, so you can be very creative. It's science-based, it's not just fiction. So that's number one.

And then the other one is stop eating when you are 80% full. How do you do that? Typically we prepare these big portions and we have this plate full of food, and typically you try to finish everything because otherwise you feel guilty

Norman Swan: As you are told by your grandmother, you had to do it.

Luigi Fontana: Yes, you feel guilty to leave something on the plate, instead of one trick is to do small portions on your plate, you do a small portion, then you know you are still very hungry, you need another small portion, until you reach a point where you say, maybe I would eat another three or four tablespoons but I'll stop, I'm satisfied enough, I have a tiny bit of hunger but I'm satisfied, and that's a way to restrict your calories, the second one. Then, if you are overweight and you are trying to lose weight, then you can use a third trick which is basically fasting, vegetable fasting once or twice a week where you eat only

Norman Swan: Which is what the Greeks do.

Luigi Fontana: Yes, only raw or cooked vegetables, a wide variety, non-starchy vegetables, with a couple of tablespoons of olive oil per day because one tablespoon is 120 calories, and then you can use orange or vinegar, whatever you want. And the fourth one is eating everything in a window of six, eight hours.

So in this way if you put together high-quality plus fasting or this 80% filling, you don't have to be a monk orit's very easy, especially if you exercise, because we have clearly shown in these randomised clinical trials I was telling you about in the beginning, that if you lose weight, let's say 8% reduction in body weight with exercise or with calorie restriction, if you lose weight with calorie restriction you have a reduction in T3, triiodothyronine, it's one of the major active thyroid hormones. Therefore, you are lowering your resting metabolic rate. Whenever you are lowering your thyroid hormones

Norman Swan: So you are burning less calories, fewer calories at rest.

Luigi Fontana: Yes. Instead of if you lose the same amount of body weight and body fat by exercise you have no reduction in T3.

Norman Swan: So you balance the two.

Luigi Fontana: Exactly, so basically your metabolism is still very high, and therefore it's mandatory to always couple exercise with diet, otherwise you are lowering your resting metabolic rate, and then you are going to regainsooner or later you are going to regain all your body weight and body fat with the interests.

Norman Swan: Luigi, thank you, it's been fascinating.

Luigi Fontana: You're welcome, thank you for having me.

Norman Swan: We'll get you back when these results are published. Thank you very much.

Luigi Fontana is Professor of Medicine and Nutrition and has a chair in translational metabolic health at the University of Sydney. He has a book which came out in 2020, it's called The Path to Longevity: The Secrets to Living a Long, Happy, Healthy Life. This has been the Health Report, I'm Norman Swan.

See the rest here:
The lowdown on longevity - Health Report - ABC News

The Dog Aging Project digs deeper than ever to help our best friends live better longer – The Union Leader

Country

United States of AmericaUS Virgin IslandsUnited States Minor Outlying IslandsCanadaMexico, United Mexican StatesBahamas, Commonwealth of theCuba, Republic ofDominican RepublicHaiti, Republic ofJamaicaAfghanistanAlbania, People's Socialist Republic ofAlgeria, People's Democratic Republic ofAmerican SamoaAndorra, Principality ofAngola, Republic ofAnguillaAntarctica (the territory South of 60 deg S)Antigua and BarbudaArgentina, Argentine RepublicArmeniaArubaAustralia, Commonwealth ofAustria, Republic ofAzerbaijan, Republic ofBahrain, Kingdom ofBangladesh, People's Republic ofBarbadosBelarusBelgium, Kingdom ofBelizeBenin, People's Republic ofBermudaBhutan, Kingdom ofBolivia, Republic ofBosnia and HerzegovinaBotswana, Republic ofBouvet Island (Bouvetoya)Brazil, Federative Republic ofBritish Indian Ocean Territory (Chagos Archipelago)British Virgin IslandsBrunei DarussalamBulgaria, People's Republic ofBurkina FasoBurundi, Republic ofCambodia, Kingdom ofCameroon, United Republic ofCape Verde, Republic ofCayman IslandsCentral African RepublicChad, Republic ofChile, Republic ofChina, People's Republic ofChristmas IslandCocos (Keeling) IslandsColombia, Republic ofComoros, Union of theCongo, Democratic Republic ofCongo, People's Republic ofCook IslandsCosta Rica, Republic ofCote D'Ivoire, Ivory Coast, Republic of theCyprus, Republic ofCzech RepublicDenmark, Kingdom ofDjibouti, Republic ofDominica, Commonwealth ofEcuador, Republic ofEgypt, Arab Republic ofEl Salvador, Republic ofEquatorial Guinea, Republic ofEritreaEstoniaEthiopiaFaeroe IslandsFalkland Islands (Malvinas)Fiji, Republic of the Fiji IslandsFinland, Republic ofFrance, French RepublicFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabon, Gabonese RepublicGambia, Republic of theGeorgiaGermanyGhana, Republic ofGibraltarGreece, Hellenic RepublicGreenlandGrenadaGuadaloupeGuamGuatemala, Republic ofGuinea, RevolutionaryPeople's Rep'c ofGuinea-Bissau, Republic ofGuyana, Republic ofHeard and McDonald IslandsHoly See (Vatican City State)Honduras, Republic ofHong Kong, Special Administrative Region of ChinaHrvatska (Croatia)Hungary, Hungarian People's RepublicIceland, Republic ofIndia, Republic ofIndonesia, Republic ofIran, Islamic Republic ofIraq, Republic ofIrelandIsrael, State ofItaly, Italian RepublicJapanJordan, Hashemite Kingdom ofKazakhstan, Republic ofKenya, Republic ofKiribati, Republic ofKorea, Democratic People's Republic ofKorea, Republic ofKuwait, State ofKyrgyz RepublicLao People's Democratic RepublicLatviaLebanon, Lebanese RepublicLesotho, Kingdom ofLiberia, Republic ofLibyan Arab JamahiriyaLiechtenstein, Principality ofLithuaniaLuxembourg, Grand Duchy ofMacao, Special Administrative Region of ChinaMacedonia, the former Yugoslav Republic ofMadagascar, Republic ofMalawi, Republic ofMalaysiaMaldives, Republic ofMali, Republic ofMalta, Republic ofMarshall IslandsMartiniqueMauritania, Islamic Republic ofMauritiusMayotteMicronesia, Federated States ofMoldova, Republic ofMonaco, Principality ofMongolia, Mongolian People's RepublicMontserratMorocco, Kingdom ofMozambique, People's Republic ofMyanmarNamibiaNauru, Republic ofNepal, Kingdom ofNetherlands AntillesNetherlands, Kingdom of theNew CaledoniaNew ZealandNicaragua, Republic ofNiger, Republic of theNigeria, Federal Republic ofNiue, Republic ofNorfolk IslandNorthern Mariana IslandsNorway, Kingdom ofOman, Sultanate ofPakistan, Islamic Republic ofPalauPalestinian Territory, OccupiedPanama, Republic ofPapua New GuineaParaguay, Republic ofPeru, Republic ofPhilippines, Republic of thePitcairn IslandPoland, Polish People's RepublicPortugal, Portuguese RepublicPuerto RicoQatar, State ofReunionRomania, Socialist Republic ofRussian FederationRwanda, Rwandese RepublicSamoa, Independent State ofSan Marino, Republic ofSao Tome and Principe, Democratic Republic ofSaudi Arabia, Kingdom ofSenegal, Republic ofSerbia and MontenegroSeychelles, Republic ofSierra Leone, Republic ofSingapore, Republic ofSlovakia (Slovak Republic)SloveniaSolomon IslandsSomalia, Somali RepublicSouth Africa, Republic ofSouth Georgia and the South Sandwich IslandsSpain, Spanish StateSri Lanka, Democratic Socialist Republic ofSt. HelenaSt. Kitts and NevisSt. LuciaSt. Pierre and MiquelonSt. Vincent and the GrenadinesSudan, Democratic Republic of theSuriname, Republic ofSvalbard & Jan Mayen IslandsSwaziland, Kingdom ofSweden, Kingdom ofSwitzerland, Swiss ConfederationSyrian Arab RepublicTaiwan, Province of ChinaTajikistanTanzania, United Republic ofThailand, Kingdom ofTimor-Leste, Democratic Republic ofTogo, Togolese RepublicTokelau (Tokelau Islands)Tonga, Kingdom ofTrinidad and Tobago, Republic ofTunisia, Republic ofTurkey, Republic ofTurkmenistanTurks and Caicos IslandsTuvaluUganda, Republic ofUkraineUnited Arab EmiratesUnited Kingdom of Great Britain & N. IrelandUruguay, Eastern Republic ofUzbekistanVanuatuVenezuela, Bolivarian Republic ofViet Nam, Socialist Republic ofWallis and Futuna IslandsWestern SaharaYemenZambia, Republic ofZimbabwe

Originally posted here:
The Dog Aging Project digs deeper than ever to help our best friends live better longer - The Union Leader

5 Eating Habits You Should Know from the World’s Longest Living People Eat This Not That – Eat This, Not That

There is a breadth of knowledge currently available about nutrition and health, but we can all agree on one very fundamental truth: what you put in your body matters. After pouring through a variety of studies and articles and opinions, that much is clear. Food is medicine, and as with any medicine, it can power your body to do incredible things.

For example, food can even help you live to be 100 years old. As of 2021, over 70,000 Americans have celebrated their 100th birthdayand it turns out, what they eat matters more than almost anything else. The Blue Zone project has done research on just how centenarians do it, focusing on five "blue zone" communities where people have the most incredible longevity in the world.

From the Nicoya Peninsula in Costa Rica to Okinawa, Japan, the people in these communities all share a variety of behaviors that increase their lifespan. Community, mindset, and movement are important. But there is no match for the power of the food they nourish themselves with. We dug in deep and rounded up the top five eating habits that centenarians share.

We've heard of the 80% kitchen, 20% gym rule before, but this is a different 80% guidelineone that dates back 2,500 years. Apparently, it is tied to a Confucian mantra that is called "hara hachi bu" in Okinawa, and it is a reminder to stop eating when you feel like you are 80% full. As the Blue Zone project puts it, "the 20% gap between not being hungry and feeling full could be the difference between losing weight or gaining it."6254a4d1642c605c54bf1cab17d50f1e

Sign up for our newsletter!

Depending on your eating hours, intermittent fasting may be a version of this tactic. The idea here is that as it gets later in the day, the human body should consume fewer calories. In the Blue Zones, people tend to eat their smallest meal lastand not very late at nightand then don't eat for the rest of the day. Great news for those of us who like big breakfasts!

Beans, beans, the magical fruit. Apparently, their magic extends all the way into life expectancya bean-rich diet is the core of most centenarian lifestyles. This can mean fava beans, black beans, and even soybeans and lentils. For more on just how healthy beans really are, check out our research on the Secret Side Effects of Eating Beans.

Perhaps this is less surprising, given the increasing societal shift away from meat towards plant-based diets. On average, people in blue zones eat meat only five times per month. The detail that might shock you, though, here? The primary kind of meat consumed is pork.

Here is another hack that has been widely promoted across many health channels, but the centenarians confirmed it: serving size is, in fact, key. According to the Blue Zone Project, serving sizes are typically kept between 3 to 4-ounces, which is about the size of a deck of cards. To get a handle on serving sizes, here are 18 Easy Ways to Control Your Portion Sizes.

Kaley Roberts

Here is the original post:
5 Eating Habits You Should Know from the World's Longest Living People Eat This Not That - Eat This, Not That

Life Lessons From the Second-Oldest Human Being to Ever Live – InsideHook

Kane Tanaka, a Japanese woman who shared a birth year with the likes of George Orwell, Lou Gehrig and Bing Crosby, passed away last week at the age of 119, as CNN reported. According to longevity researchers she was the second-oldest verified human being to ever live, and the oldest ever from a country thats famous for producing centenarians.

Tanaka had been in the news a bit in recent years she was poised to play a part in the Olympic torch ceremony ahead of the 2020 Summer Olympics in Tokyo, but her family and Games officials scrapped the plan once the COVID-19 pandemic arrived. (Many publications pointed out at the time that Tanaka was one of the few people on the planet to live through both the 1918 influenza pandemic which started when she was 15 and the coronavirus pandemic.)

She lived through quite a bit, in fact: two world wars, five Japanese imperial reigns, 21 American presidencies, a dramatic industrialization of her home country and unthinkable global population growth. At the time of Tanakas birth, there were fewer than two billion people living on the planet. That number is now up to nearly eight billion.

Tanakas life was local, quiet and remarkably consistent. She married at the age of 19 and worked in a family shop that sold udon noodles into the age of 103. (Her husband passed away at the age of 90, after 71 years of marriage.) Her last few years were spent in a nursing home, and according to her family, she was frequently sick over the last few months. She falls a little over eight months short of her recent goal to live to 120.

Its remarkable that Tanaka lived as long as she did, though, considering she suffered from a variety of serious ailments and illnesses over the decades, including paratyphoid fever, pancreatic cancer and colorectal cancer. Her life along with those of other so-called supercentenarians lends credence to latter-day scientific thinking that the human lifespan does not have a ceiling, but is actually heavily influenced by lifestyle and behaviors.

(Some scientists have suggested that ages 40 years above todays average life expectancy as attainable for future generations. And with future medicine, which will lean heavily on cellular reprogramming, theres no telling how long a human being could live. Is 200 years within reach? Many geneticists now say Why not?)

For her part, Tanaka appeared to casually observe two of the most important tenets of longterm health: curiosity and community. She kept her brain curious and agile, solving mathematics problems as a hobby; and she played an integral role in the world around her, engaging every day with family, customers and other members of her faith. (Tanaka was a devout Christian. Whatever your views on faith, engagement in religious communities has long been linked to longevity in Blue Zones throughout the planet.)

She reportedly made sure to eat and sleep well, too, which are essential to longterm health, but not in a manner that so many in the Western world have adopted, treating personal nutrition as some sort of punitive contest. Tanaka allowed herself treats, and retained her mirth. Years ago, she posed for her birthday photo while holding up a bottle of her beloved Coca-Cola.

Thanks for reading InsideHook. Sign up for our daily newsletter and be in the know.

Read the original:
Life Lessons From the Second-Oldest Human Being to Ever Live - InsideHook